



**Clinical Study Protocol**

Sponsor:  
**Pfizer, Inc.**  
235 East 42nd Street  
New York, NY 10017, United States

<b>Primary Study vaccines</b>	Meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine (Nimenrix <sup>®</sup> , PF-06866681).
<b>Other Study vaccine(s)</b>	NA
<b>Study number and Abbreviated Title</b>	C0921005 (MENACWY-TT-101 EXT:036 Y10; formerly GSK 116724)
<b>European Clinical Trials Database (EudraCT) Number</b>	2013-001512-29
<b>Date of protocol</b>	Final Version 2: 03 July 2013
<b>Date of protocol amendment</b>	Amendment 1 Final: 23 October 2013 Amendment 2 Final: 25 February 2016 Amendment 3 Final: 12 July 2017
<b>Title</b>	Immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine (PF-06866681).
<b>Detailed Title</b>	A phase IIIb, open study to evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix <sup>®</sup> ) or Mencevax ACWY <sup>®</sup> .

## Protocol Amendment 3 Sponsor Signatory Approval

<b>Study number and Abbreviated Title</b>	C0921005 (MENACWY-TT-101 EXT:036 <i>Y10</i> ; formerly GSK 116724)
<b>EudraCT number</b>	2013-001512-29
<b>Date of protocol</b>	Final Version 2: 03 July 2013
<b>Date of protocol amendment</b>	Amendment 1 Final: 23 October 2013 Amendment 2 Final: 25 February 2016 Amendment 3 Final: 12 July 2017
<b>Detailed Title</b>	A phase IIIb, open study to evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered <i>10</i> years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix®) or Mencevax ACWY®.
<b>Sponsor signatory</b>	PPD [REDACTED] MD PPD [REDACTED] Pfizer Vaccines Clinical Research
<b>Signature</b>	<hr/>
<b>Date</b>	<hr/>

090177e19088c6d6\Approved\Approved On: 11-Mar-2019 09:45 (GMT)

## Document History

Document	Version Date	Summary of Changes and Rationale
Amendment 3	12 July 2017	<p>Changes were made based on the protocol administration clarification letter that was distributed to sites and included an update to <a href="#">Table 4</a> to indicate that pre-vaccination assessment of contraception does not require documentation in the individual case report form (CRF)/electronic case report form (eCRF).</p> <p>A minor editorial change was made in Section <a href="#">6.3</a> Dosage and Administration of Study Vaccine.</p> <p>Blood draw was increased to up to 50 mL of whole blood at Visit 2 (1 month-post booster vaccination) for a subset of consenting subjects. Several changes were made throughout this protocol amendment to adjust blood volumes collected at Visit 2 for this subset. Changes were made to the following sections:</p> <p>Section <a href="#">1.2</a></p> <p>Section <a href="#">5.5 Table 4</a></p> <p>Section <a href="#">5.6.1</a></p> <p>Section <a href="#">5.6.12.1</a></p> <p>Section <a href="#">5.7.2 Table 6</a></p>

Amendment 2	25 February 2016	<ul style="list-style-type: none"> <li>• Protocol amended to reflect sponsorship change to Pfizer following the acquisition of the GSK meningococcal vaccine Nimenrix by Pfizer on 01 October 2015.</li> <li>• Sponsor name updated throughout the protocol to Pfizer.</li> <li>• Blood sample volume increased to 10 mL for pre- and postbooster samples.</li> <li>• Sections updated / added in line with standard Pfizer policy: <ul style="list-style-type: none"> <li>• Synopsis – Secondary immunogenicity objectives</li> <li>• 1.1 Background</li> <li>• 1.2 Rationale for the study and study design</li> <li>• 1.3 Benefit : Risk assessment</li> <li>• 2.2 Secondary objectives</li> <li>• 4.2 Inclusion criteria for enrolment</li> <li>• 4.3 Exclusion criteria for enrolment</li> <li>• 5.1 Regulatory and ethical considerations including the informed consent process</li> <li>• 5.2 Subject identification and randomisation of treatment</li> <li>• 5.5 Outline of study procedures</li> <li>• 5.6.9 Pre-Vaccination assessment of contraception</li> </ul> </li> </ul>
-------------	------------------	--

		<ul style="list-style-type: none"> <li>• 5.6.10 Urine pregnancy test</li> <li>• 5.7 Biological sample handling and analysis</li> <li>• 6 Study vaccine and administration</li> <li>• 8.1.1 Definition of an adverse event</li> <li>• 8.1.2 Medication errors</li> <li>• 8.1.3 Occupational exposure</li> <li>• 8.1.4 Exposure during Pregnancy</li> <li>• 8.1.5 Definition of a serious adverse event</li> <li>• 8.1.6.1 Solicited local (injection-site) adverse events</li> <li>• 8.2.1 Time period for detecting and recording adverse events, serious adverse events and pregnancies</li> <li>• 8.2.2 Post-Study adverse events and serious adverse events</li> <li>• 8.2.3 Evaluation of adverse events and serious adverse events</li> <li>• 8.3 Reporting of serious adverse events, pregnancies, and other events</li> <li>• 8.6 Subject card</li> <li>• 9.2 Subject withdrawal</li> <li>• 9.2.1 Subject withdrawal from the study</li> <li>• 9.2.2 Subject withdrawal from study vaccine</li> </ul>
--	--	--

		<ul style="list-style-type: none"> <li>• 10.4 Study cohorts/data sets to be analysed</li> <li>• 10.6 Statistical analyses</li> <li>• 11.3 Record retention</li> <li>• 11.5 Posting of information on publicly available clinical trial registers and publication policy</li> <li>• 11.6 Provision of study results to investigators</li> <li>• 11.7 Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP</li> <li>• Appendix A Laboratory Assays</li> <li>• Appendix B Clinical laboratories</li> <li>• Additions to the glossary (including the clarification of contraception/abstinence)</li> <li>• List of Abbreviations</li> <li>• Trademarks</li> <li>• Table 4 changes (including prevaccination assessment of contraception, related SAEs, and pregnancy as an exclusion criterion)</li> <li>• Taking into consideration the timelines for regulatory submission and approval in the Philippines, the planned study start for booster vaccination has been delayed. To allow all subjects to receive their booster vaccination, Visit 1 will occur at 10 years after the primary vaccination in study MENACWY-TT-036. The study will only have two time</li> </ul>
--	--	--

		<p>points including the booster vaccination visit at Month 120 and the one month post-booster vaccination visit at Month 121. As a result, antibody persistence after booster vaccination will not be assessed in the current study.</p> <ul style="list-style-type: none"> <li>• The Document Standard template version was promoted from v14.0 to v14.1.1. To this end, the Section on Benefit:Risk Assessment was added (Section 1.3) and revisions made to biological specimens (Section 5.7).</li> <li>• The total number of subjects expected to participate in the study and details related to sample size have been updated.</li> <li>• In addition, minor editorial changes were made.</li> </ul>
Amendment 1	23 October 2013	Not applicable (NA)
Original protocol	03-July-2013	Not applicable (NA)

This amendment incorporates all revisions to date, including amendments made at the request of country health authorities, institutional review boards/ethics committees (IRBs/ECs), etc.

## Protocol Amendment 3 Investigator Agreement

I agree:

- To conduct the study in compliance with this protocol, any future protocol amendments or protocol administrative changes, with the terms of the clinical trial agreement and with any other study conduct procedures and/or study conduct documents provided by Pfizer.
- To assume responsibility for the proper conduct of the study at this site.
- That I am aware of, and will comply with, 'Good Clinical Practice' and all applicable regulatory requirements.
- To ensure that all persons assisting me with the study are adequately informed about the Pfizer investigational vaccine and other study-related duties and functions as described in the protocol.
- To acquire the reference ranges for laboratory tests performed locally and, if required by local regulations, obtain the laboratory's current certification or Quality Assurance procedure manual.
- To ensure that no clinical samples (including serum samples) are retained onsite or elsewhere without the approval of Pfizer and the express written informed consent of the subject and/or the subject's legally acceptable representative.
- To perform no other biological assays on the clinical samples except those described in the protocol or its amendment(s).
- To co-operate with a representative of Pfizer in the monitoring process of the study and in resolution of queries about the data.
- That I have been informed that certain regulatory authorities require the sponsor to obtain and supply, as necessary, details about the investigator's ownership interest in the sponsor or the investigational vaccine, and more generally about his/her financial ties with the sponsor. Pfizer will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I:

- Agree to supply Pfizer with any necessary information regarding ownership interest and financial ties (including those of my spouse and dependent children).
- Agree to promptly update this information if any relevant changes occur during the course of the study and for one year following completion of the study.
- Agree that Pfizer may disclose any information it has about such ownership interests and financial ties to regulatory authorities.
- Agree to provide Pfizer with an updated Curriculum Vitae and other documents required by regulatory agencies for this study.



<b>Study number and Abbreviated Title</b>	C0921005 (MENACWY-TT-101 EXT:036 Y10; formerly GSK 116724)
<b>EudraCT number</b>	2013-001512-29
<b>Date of protocol</b>	Final Version 2: 03 July 2013
<b>Date of protocol amendment</b>	Amendment 1 Final: 23 October 2013 Amendment 2 Final: 25 February 2016 Amendment 3 Final: 12 July 2017
<b>Detailed Title</b>	A phase IIIb, open study to evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix <sup>®</sup> ) or Mencevax ACWY <sup>®</sup> .
<b>Investigator name</b>	<hr/>
<b>Signature</b>	<hr/>
<b>Date</b>	<hr/>

## SYNOPSIS

<b>Detailed Title</b>	A phase IIIb, open study to evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix <sup>®</sup> ) or Mencevax ACWY <sup>®</sup> .
<b>Indication</b>	Active immunization against invasive meningococcal disease caused by <i>Neisseria meningitidis</i> serogroups A, C, W-135 and Y in healthy subjects aged 11 to 17 years of age.
<b>Rationale for the study and study design</b>	<p>Subjects aged 11-17 years of age were vaccinated with one dose of either MenACWY-TT or <i>Mencevax ACWY</i> in study MenACWY-TT-036 (109069). The participants from India and the Philippines were further followed for the assessment of persistence in study MenACWY-TT-043 (112148). Unless they withdrew their consent, subjects were invited for a yearly blood sample, regardless of their serostatus at the previous persistence time point, up to Year 5 after primary vaccination. Five years after vaccination the percentage of subjects with rSBA titres <math>\geq 1:8</math> for the 4 meningococcal serogroups A, C, W-135, and Y ranged between 86.0% - 97.5% in the <i>Nimenrix</i> vaccinees and between 34.9% - 93.0% in the subjects vaccinated with <i>Mencevax ACWY</i>.</p> <p>A booster dose 5 years after vaccination has already been assessed in individuals primed at the age of 11-25 years. The purpose of this study is to evaluate the safety and immunogenicity of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either a single dose of meningococcal serogroup ACWY tetanus toxoid conjugate (MenACWY-TT) vaccine or <i>Mencevax ACWY</i>. The primary vaccination study MenACWY-TT-036 (109069) was conducted in India, the Philippines and Taiwan. The MenACWY-TT-043 (112148) persistence study up to Year 5 after primary vaccination included only India and the Philippines. Due to Good Clinical Practice issues in India, this booster study will only be conducted in the Philippines.</p>
<b>Objectives</b>	<p><b>Primary</b></p> <p><b>One month post-booster vaccination with MenACWY-TT vaccine in each of the study groups:</b></p> <ul style="list-style-type: none"> <li>To evaluate the immunogenicity of a booster dose of MenACWY-TT conjugate vaccine in terms of the</li> </ul>

percentage of subjects with an rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY Booster response\*.

\*Booster response to meningococcal antigens (A, C, W-135 and Y) is defined as:

- For initially seronegative subjects (pre-vaccination rSBA titer below 1:8): rSBA antibody titer  $\geq$  1:32 one month after vaccination, and
- For initially seropositive subjects (pre-vaccination rSBA titer  $\geq$  1:8): at least four-fold increase in rSBA titers from pre-vaccination to one month after vaccination.

## Secondary

### Secondary immunogenicity objectives:

#### One month post-booster vaccination with MenACWY-TT vaccine:

- To evaluate the immunogenicity of a booster dose of MenACWY-TT conjugate vaccine with respect to the percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody titers  $\geq$  1:8,  $\geq$  1:128 and Geometric Mean Titres (GMTs).

#### Pre-booster and one month post-booster vaccination with MenACWY-TT vaccine:

- To evaluate the percentage of subjects with anti-TT concentrations  $\geq$  0.1 IU/mL,  $\geq$  1.0 IU/mL and Geometric Mean Concentrations (GMCs).

#### Long-term persistence phase ten years after primary vaccination with MenACWY-TT or *Mencevax ACWY* in Study MenACWY-TT-036 (109069):

- To evaluate the long-term antibody persistence induced by MenACWY-TT conjugate vaccine as compared to *Mencevax ACWY* when administered to individuals 11-17 years of age with respect to the percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody titers  $\geq$  1:8,  $\geq$  1:128 and GMTs.

### Secondary safety objectives:

- To evaluate the safety and reactogenicity of a booster dose of MenACWY-TT conjugate vaccine.
- To describe Serious Adverse Events (SAEs) related to

study vaccination and any event related to lack of vaccine efficacy (i.e. meningococcal disease) from the subject's last visit in study MenACWY-TT-036 (109069) or in study MenACWY-TT-043 EXT:036 Y2, 3, 4, 5 (112148).\*

\*last visit in study MenACWY-TT-036 (109069) will only be considered for subjects who did not participate in study MenACWY-TT-043 EXT:036 Y2, 3, 4, 5 (112148).

### Study design

- Experimental design: Phase IIIb, open study with two parallel groups: ACWY-TT group: vaccinated with MenACWY-TT in study MenACWY-TT-036 (109069), MenPS group: vaccinated with *Mencevax ACWY* in study MenACWY-TT-036 (109069).
- Duration of the study: Approximately one month for each subject
- Study groups:

**Synopsis Table 1 Study groups and epochs foreseen in the study**

Study Groups	Number of subjects	Approximate Age (Min - Max) (age unit)	Epoch 001
ACWY-TT	150	20 years –28 years	x
MenPS	50	20 years –28 years	x

\*The sample size of this study with respect to the analysis of immunogenicity, reactogenicity and safety post MenACWY-TT booster vaccination is driven by a) the sample size of the primary vaccination study MenACWY-TT-036 (109069) in the participating site and b) assumptions about the enrolment rate at the present extension study. For more information, see Section 10.3.

**Synopsis Table 2 Study groups and treatment foreseen in the study**

Treatment name	Vaccine/Product name	Study Groups	
		ACWY-TT	MenPS
MenACWY-TT	MenACWY-TT	x	x
	NaCl*	x	x

\*The lyophilized pellet of MenACWY-TT vaccine is to be reconstituted with the supplied saline solution.

- Control: uncontrolled.
- Vaccination schedule: At Visit 1 (Month 120 post primary vaccination), one dose of MenACWY-TT conjugate vaccine will be administered to all subjects in both study groups.
- Treatment allocation: The subjects in this study will be allocated to the same groups as in the vaccination study MenACWY-TT-036 (109069). Subjects will be allocated

a new container number, but will retain the same subject number as in MenACWY-TT-036.

- Blinding: Study will be conducted in an open manner.

**Synopsis Table 3 Blinding of study epoch**

Study Epochs	Blinding
Epoch 001	Open

- Sampling schedule: Two blood samples for each subject enrolled:
  - prior to booster vaccination,
  - one month after booster vaccination.
- Type of study: extension of other protocol(s): (MenACWY-TT-036 [109069]; MenACWY-TT-043EXT:036 Y2, 3, 4 and 5 [112148]).
- Data collection: Electronic Case Report Form (eCRF).

**Number of subjects** All subjects vaccinated with meningococcal vaccine in study MenACWY-TT-036 (109069) from the participating site in the Philippines will be considered for invitation to participate in this study. It is expected that approximately 200 subjects from the participating site in the Philippines will participate in this extension study.

### Endpoints

#### Primary

Immunogenicity with respect to the components of the investigational vaccine one month after booster vaccination with MenACWY-TT vaccine (primary readouts):

- rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA MenY booster response\*.

\*Booster response to meningococcal antigens (A, C, W 135 and Y) is defined as:

- For initially seronegative subjects (pre-vaccination rSBA titer below 1:8): rSBA antibody titer  $\geq$  1:32 one month after vaccination, and
- For initially seropositive subjects (pre-vaccination rSBA titer  $\geq$  1:8): at least four-fold increase in rSBA titers from pre-vaccination to one month after vaccination.

## Secondary

Immunogenicity with respect to the components of the investigational vaccine prior to and one month after booster vaccination with MenACWY-TT vaccine (secondary readouts):

- rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres  $\geq 1:8$ ,  $\geq 1:128$  and GMTs.
- Anti-TT concentrations  $\geq 0.1$  IU/mL,  $\geq 1.0$  IU/mL and GMCs.

Safety and reactogenicity:

- Occurrence of solicited local and general symptoms within 4 days (Day 0 to Day 3) after MenACWY-TT booster vaccination.
- Occurrence of unsolicited adverse events, within 31 days (Day 0 to Day 30) after MenACWY-TT booster vaccination.
- Occurrence of all SAEs, Guillain-Barré syndrome and new onset of chronic illness(es) [e.g. asthma, autoimmune disorders, type I diabetes, allergies] within 31 days (Day 0 to Day 30) after MenACWY-TT booster vaccination.
- Occurrence of SAEs related to primary vaccination and any event related to lack of vaccine efficacy (i.e. meningococcal disease) from the subject's last visit in the primary study MenACWY-TT-036 (109069) or in the persistence study MenACWY-TT-043EXT:036 Y2, 3, 4, 5 (112148) until entry in study C0921005 (MenACWY-TT-101 EXT:036 Y10) (116724).

**TABLE OF CONTENTS**

	<b>PAGE</b>
SYNOPSIS.....	10
LIST OF ABBREVIATIONS .....	21
GLOSSARY OF TERMS .....	24
TRADEMARKS .....	28
1. INTRODUCTION.....	29
1.1. Background .....	29
1.2. Rationale for the study and study design .....	30
1.3. Benefit : Risk Assessment .....	30
1.3.1. Risk Assessment .....	30
1.3.2. Benefit Assessment .....	32
1.3.3. Overall Benefit:Risk Conclusion .....	32
2. OBJECTIVES.....	33
2.1. Primary objective .....	33
2.2. Secondary objectives.....	33
3. STUDY DESIGN OVERVIEW .....	34
4. STUDY COHORT.....	36
4.1. Number of subjects/centres .....	36
4.2. Inclusion criteria for enrolment .....	36
4.3. Exclusion criteria for enrolment.....	37
5. CONDUCT OF THE STUDY .....	38
5.1. Regulatory and ethical considerations, including the informed consent process.....	38
5.2. Subject identification and randomisation of treatment .....	39
5.2.1. Subject identification.....	39
5.2.1.1. Treatment allocation to the subject.....	39
5.2.1.1.1. Study group and container number allocation .....	39
5.3. Method of blinding .....	40
5.4. General study aspects .....	40
5.5. Outline of study procedures .....	41
5.6. Detailed description of study procedures .....	42
5.6.1. Informed consent .....	42
5.6.2. Check inclusion and exclusion criteria .....	43
5.6.3. Collect demographic data .....	43
5.6.4. Check contraindications, warnings and precautions to vaccination.....	43
5.6.5. Medical history.....	43
5.6.6. Recording of meningococcal and TT vaccination history.....	43
5.6.7. History directed physical examination .....	43

12 July 2017

5.6.8.	Assess pre-vaccination body temperature .....	43
5.6.9.	Pre-Vaccination assessment of contraception .....	44
5.6.10.	Urine pregnancy test.....	44
5.6.11.	Container number allocation .....	44
5.6.12.	Sampling.....	44
5.6.12.1.	Blood sampling for safety or immune response assessments .....	44
5.6.13.	Study Vaccine administration.....	45
5.6.14.	Check and record concomitant medication/vaccination and intercurrent medical conditions .....	45
5.6.15.	Recording of AEs, SAEs and pregnancies.....	45
5.6.15.1.	Recording of GBS and New Onset of Chronic Illnesses (NOCIs) .....	46
5.6.16.	Study conclusion.....	46
5.7.	Biological sample handling and analysis.....	46
5.7.1.	Use of specified study materials .....	47
5.7.2.	Biological samples .....	47
5.7.3.	Laboratory assays .....	47
5.7.4.	Biological samples evaluation .....	48
5.7.4.1.	Immunological read-outs .....	48
5.7.5.	Immunological correlates of protection.....	48
6.	STUDY VACCINE AND ADMINISTRATION.....	49
6.1.	Description of study vaccine .....	49
6.2.	Storage and handling of study vaccine .....	50
6.3.	Dosage and administration of study vaccine .....	51
6.4.	Warnings and precautions .....	51
6.5.	Concomitant medication/product and concomitant vaccination .....	52
6.5.1.	Recording of concomitant medications/products and concomitant vaccination.....	52
6.5.2.	Concomitant medications/products/vaccines that may lead to the elimination of a subject from ATP analyses.....	52
6.6.	Intercurrent medical conditions that may lead to elimination of a subject from ATP analyses .....	53
7.	HEALTH ECONOMICS .....	53
8.	SAFETY .....	53
8.1.	Safety definitions .....	54
8.1.1.	Definition of an adverse event.....	54
8.1.2.	Medication Errors.....	55
8.1.3.	Occupational Exposure.....	55
8.1.4.	Exposure During Pregnancy .....	56
8.1.5.	Definition of a serious adverse event .....	57
8.1.6.	Solicited adverse events .....	58
8.1.6.1.	Solicited local (injection-site) adverse events.....	58
8.1.6.2.	Solicited general adverse events .....	58
8.1.7.	Clinical laboratory parameters and other abnormal assessments qualifying as adverse events or serious adverse events .....	59
8.1.8.	Adverse events of specific interest.....	59
8.1.8.1.	List of New Onset of Chronic Illnesses .....	59



8.1.9.	Pregnancy .....	62
8.2.	Detecting and recording adverse events, serious adverse events and pregnancies .....	63
8.2.1.	Time period for detecting and recording adverse events, serious adverse events and pregnancies .....	63
8.2.2.	Post-Study adverse events and serious adverse events .....	66
8.2.3.	Evaluation of adverse events and serious adverse events .....	66
8.2.3.1.	Active questioning to detect adverse events and serious adverse events .....	66
8.2.3.2.	Assessment of adverse events .....	67
8.2.3.2.1.	Assessment of intensity .....	67
8.2.3.2.2.	Assessment of causality .....	68
8.2.3.3.	Assessment of outcomes .....	69
8.2.3.4.	Medically attended visits .....	70
8.2.3.5.	Adverse events of specific interest .....	70
8.3.	Reporting of serious adverse events, pregnancies, and other events .....	70
8.3.1.	Prompt reporting of serious adverse events, pregnancies, and other events .....	70
8.3.2.	Completion and transmission of SAE reports .....	71
8.3.3.	Completion and transmission of pregnancy reports .....	71
8.3.4.	Updating of SAE and pregnancy information after <i>removal of write access to the subject's eCRF</i> .....	71
8.3.5.	Regulatory reporting requirements for serious adverse events .....	72
8.4.	Follow-up of adverse events, serious adverse events, and pregnancies .....	72
8.4.1.	Follow-up of adverse events and serious adverse events .....	72
8.4.1.1.	Follow-up during the study .....	72
8.4.1.2.	Follow-up after the subject is discharged from the study .....	72
8.4.2.	Follow-up of pregnancies .....	73
8.5.	Treatment of adverse events .....	73
8.6.	Subject card .....	73
9.	SUBJECT COMPLETION AND WITHDRAWAL .....	74
9.1.	Subject completion .....	74
9.2.	Subject withdrawal .....	74
9.2.1.	Subject withdrawal from the study .....	74
9.2.2.	Subject withdrawal from study vaccine .....	75
10.	STATISTICAL METHODS .....	75
10.1.	Primary endpoint .....	75
10.2.	Secondary endpoints .....	76
10.3.	Determination of sample size .....	76
10.4.	Study cohorts/ data sets to be analysed .....	77
10.4.1.	Booster Total Vaccinated cohort .....	77
10.4.2.	Booster According-to-protocol cohort for safety .....	77
10.4.3.	Booster According-to-protocol cohort for immunogenicity .....	78
10.4.4.	Total cohort at Month 120 .....	78
10.4.5.	According-to-protocol cohort for persistence at Month 120 .....	78
10.5.	Derived and transformed data .....	79

10.5.1.	Immunogenicity.....	79
10.6.	Statistical analyses .....	79
10.6.1.	Analysis of demographics/baseline characteristics .....	79
10.6.2.	Analysis of post-booster immunogenicity .....	80
10.6.2.1.	Within group analysis .....	80
	CCI	
10.6.3.	Analysis of antibody persistence .....	80
10.6.3.1.	Within group analysis .....	81
	CCI	
10.6.4.	Analysis of reactogenicity and safety .....	81
10.7.	Interpretation of analyses.....	82
10.8.	Conduct of analyses .....	82
10.8.1.	Sequence of analyses.....	82
11.	ADMINISTRATIVE MATTERS .....	83
11.1.	electronic Case Report Form instructions .....	83
11.2.	Study Monitoring.....	83
11.3.	Record retention .....	84
11.4.	Quality assurance .....	84
11.5.	Posting of information on publicly available clinical trial registers and publication policy .....	85
11.6.	Provision of study results to investigators .....	85
11.7.	Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP.....	87
12.	COUNTRY SPECIFIC REQUIREMENTS.....	87
13.	REFERENCES.....	87

**LIST OF TABLES**

	<b>PAGE</b>
Table 1 Study groups and epochs foreseen in the study .....	35
Table 2 Study groups and treatment foreseen in the study .....	35
Table 3 Blinding of study epochs .....	35
Table 4 List of study procedures .....	41
Table 5 Intervals between study visits .....	42
Table 6 Biological samples for the ACWY-TT and MenPS groups .....	47
Table 7 Humoral Immunity (Antibody determination).....	48
Table 8 Immunological read-outs .....	48
Table 9 Study vaccine.....	50
Table 10 Dosage and administration.....	51
Table 11 Solicited local adverse events .....	58
Table 12 Solicited general adverse events.....	59
Table 13 List of NOCIs.....	60
Table 14 Reporting periods for adverse events, serious adverse events and pregnancies.....	65
Table 15 Intensity scales for solicited symptoms.....	67
Table 16 Timeframes for submitting serious adverse event, exposure during pregnancy and other events reports .....	71
Table 17 Exact 95% confidence intervals of the percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY booster response .....	77
Table 18 Outsourced laboratories .....	92

**LIST OF FIGURES**

	<b>PAGE</b>
Figure 1 Study design diagram .....	34

**LIST OF APPENDICES**

	<b>PAGE</b>
APPENDIX A LABORATORY ASSAYS .....	91
APPENDIX B CLINICAL LABORATORIES .....	92

## LIST OF ABBREVIATIONS

<b>AE</b>	Adverse Event
<b>ANOVA</b>	Analysis of Variance
<b>ATP</b>	According to Protocol
<b>CDC</b>	Centers for Disease Control and Prevention, US
<b>CDS</b>	Core Data Sheet
<b>CI</b>	Confidence Interval
<b>CRF</b>	Case Report Form
<b>CRM<sub>197</sub></b>	Non-toxic mutant form of the diphtheria toxin
<b>CSA</b>	Clinical Study Agreement
<b>dLIA</b>	Direct Luminex Immunoassay
<b>DU</b>	Dispensible Unit
<b>EC</b>	Ethics Committee
<b>eCRF</b>	Electronic Case Report Form
<b>EDP</b>	Exposure During Pregnancy
<b>EGA</b>	Estimated Gestational Age
<b>ELISA</b>	Enzyme-Linked Immunosorbent Assay
<b>EMA</b>	European Medicines Agency
<b>EU</b>	European Union
<b>EudraCT</b>	European Clinical Trials Database
<b>FDA</b>	Food and Drug Administration, US
<b>GBS</b>	Guillain-Barré Syndrome
<b>GCP</b>	Good Clinical Practice
<b>GMC</b>	Geometric Mean Concentration
<b>GMT</b>	Geometric Mean Titre

090177e19088c6d6\Approved\Approved On: 11-Mar-2019 09:45 (GMT)

<b>GSK</b>	GlaxoSmithKline
<b>HPA</b>	Health Protection Agency
<b>IAF</b>	Informed Assent Form
<b>ICD</b>	International Classification of Diseases
<b>ICF</b>	Informed Consent Form
<b>ICH</b>	International Conference on Harmonisation
<b>IEC</b>	Independent Ethics Committee
<b>IM</b>	Intramuscular(ly)
<b>IMP</b>	Investigational Medicinal Product
<b>IRB</b>	Institutional Review Board
<b>IRT</b>	Interactive Response Technology
<b>LAR</b>	Legally Acceptable Representative
<b>LL</b>	Lower Limit
<b>LLOQ</b>	Lower Limit of Quantitation
<b>LMP</b>	Last Menstrual Period
<b>MedDRA</b>	Medical Dictionary for Regulatory Activities
<b>MenA</b>	<i>N. meningitidis</i> serogroup A
<b>MenC</b>	<i>N. meningitidis</i> serogroup C
<b>MenW-135</b>	<i>N. meningitidis</i> serogroup W
<b>MenY</b>	<i>N. meningitidis</i> serogroup Y
<b>mL</b>	milliliter(s)
<b>NA</b>	Not Applicable
<b>NOCI</b>	New Onset of Chronic Illness(es)
<b>PHE</b>	Public Health England (previously the Health Protection Agency [HPA])

<b>pIMD</b>	Potential Immune-Mediated Disorder
<b>rSBA</b>	Serum Bactericidal Assay (using baby rabbit complement)
<b>rSBA-MenA</b>	Serum Bactericidal Assay/activity against <i>N. meningitidis</i> serogroup A (using baby rabbit complement)
<b>rSBA-MenC</b>	Serum Bactericidal Assay/activity against <i>N. meningitidis</i> serogroup C (using baby rabbit complement)
<b>rSBA-MenW-135</b>	Serum Bactericidal Assay/activity against <i>N. meningitidis</i> serogroup W-135 (using baby rabbit complement)
<b>rSBA-MenY</b>	Serum Bactericidal Assay/activity against <i>N. meningitidis</i> serogroup Y (using baby rabbit complement)
<b>SAE</b>	Serious Adverse Event
<b>SBA</b>	Serum Bactericidal Assay
<b>SDV</b>	Source Data Verification
<b>SPM</b>	Study Procedures Manual
<b>SRSD</b>	Single Safety Reference Document
<b>TT</b>	Tetanus Toxoid
<b>µg</b>	Microgram(s)
<b>UL</b>	Upper Limit
<b>US; United States</b>	United States; United States of America
<b>WHO</b>	World Health Organization

## GLOSSARY OF TERMS

**Adequate contraception:** Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label for example:

- abstinence from penile-vaginal intercourse, when this is the subject's preferred and usual lifestyle (any version of temporary or episodic abstinence is not considered adequate contraception),
- oral contraceptives, either combined or progestogen alone,
- injectable progestogen,
- implants of etenogestrel or levonorgestrel,
- estrogenic vaginal ring,
- percutaneous contraceptive patches,
- intrauterine device or intrauterine system,
- male partner sterilisation prior to the female subject's entry into the study, and this male is the sole partner for that subject,

The information on the male sterility can come from the site personnel's review of the subject's medical records; or interview with the subject on her medical history.

- male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository),
- male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).

Adequate contraception does not apply to subjects of child bearing potential with same sex partners, when this is their preferred and usual lifestyle.



<b>Adverse event:</b>	Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.  An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.
<b>Blinding:</b>	In an open-label study, no blind is used. Both the investigator and the subject know the identity of the treatment assigned.
<b>Container Number</b>	A number identifying a treatment to a subject, according to the study randomisation or treatment allocation.
<b>Core Data Sheet (CDS):</b>	The Core Data Sheet (CDS) represents the internal company medical position for all labeling documents worldwide. The CDS is a document containing all essential safety information, such as contraindications, warnings/precautions, and undesirable effects, which Pfizer requires to be included in the proposed labeling of all countries where the product is marketed. The Core Data Sheet also contains indications and dosing information (for all dosage forms) supported worldwide, as well as pharmacodynamic, pharmacokinetic and non-clinical information that has important bearing on the safe and effective use of the product. Information contained in the Core Data Sheet is based on valid, scientific/medical data. The Core Data Sheet is a vehicle by which information on a marketed product is communicated to the appropriate stakeholders worldwide.
<b>Eligible:</b>	Qualified for enrolment into the study based upon strict adherence to inclusion/exclusion criteria.
<b>Epoch:</b>	An epoch is a self-contained set of consecutive time points or a single time point from a single protocol. Self-contained means that data collected for all subjects at all time points within that epoch allows to draw a complete conclusion to define or precise the targeted label of the product. Typical examples of epochs are primary vaccinations, boosters, yearly immunogenicity follow-

ups, and surveillance periods for efficacy or safety.

<b>Evaluable:</b>	Meeting all eligibility criteria, complying with the procedures defined in the protocol, and, therefore, included in the according-to-protocol (ATP) analysis (see Sections 6.5.2 and 10.4 for details on criteria for evaluability).
<b>Menarche:</b>	Menarche is the onset of menses for the first time in a young female and is preceded by changes associated with puberty including breast development and pubic hair growth. Menarche usually occurs within 1-2 years of breast development, thelarche. However, a young female can become pregnant before her first menses. Thus, a conservative definition of non-childbearing potential in a pre-menarcheal female is a young female who has not yet entered puberty as evidenced by lack of breast development (palpable glandular breast tissue).
<b>Immunological correlate of protection:</b>	The defined humoral antibody response above which there is a high likelihood of protection in the absence of any host factors that might increase susceptibility to the infectious agent.
<b>Investigational vaccine/product:</b>  <b>(Synonym of Investigational Medicinal Product)</b>	A pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, including a product with a marketing authorisation when used in a way different from the approved form, or when used for an unapproved indication, or when used to gain further information about an approved use.
<b>Potential Immune-Mediated Disorder:</b>	Potential immune-mediated disorders are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
<b>Post-menopause</b>	Achieved post-menopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; status may be confirmed by a serum follicle-stimulating hormone (FSH) level confirming the post-menopausal state.
<b>Randomisation:</b>	Process of random attribution of treatment to subjects in order to reduce bias of selection.
<b>Self-contained study:</b>	Study with objectives not linked to the data of another

study.

<b>Site Monitor:</b>	An individual assigned by the sponsor who is responsible for assuring proper conduct of clinical studies at one or more investigational sites.
<b>Solicited adverse event:</b>	The presence/occurrence/intensity of these events is actively solicited from the subject or an observer during a specified post-vaccination follow-up period.
<b>Subject:</b>	Term used throughout the protocol to denote an individual who has been contacted in order to participate or participates in the clinical study, either as a recipient of the vaccine(s)/product(s) or as a control.
<b>Subject number:</b>	A unique number identifying a subject, assigned to each subject consenting to participate in the study.
<b>Treatment:</b>	Term used throughout the clinical study to denote a set of investigational product(s) or marketed product(s) or placebo intended to be administered to a subject, identified by a unique number, according to the study randomisation or treatment allocation.
<b>Unsolicited adverse event:</b>	Any AE reported in addition to those solicited during the clinical study. Also any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

## TRADEMARKS

The following trademarks are used in the present protocol.

Note: In the body of the protocol (including the synopsis), the names of the vaccines will be written without the superscript symbol ® and will be written in *italics*.

Trademarks of Pfizer
Nimenrix®
Mencevax ACWY®

Generic description
Meningococcal group A, C, W-135 and Y tetanus toxoid conjugate vaccine
Meningococcal serogroups A, C, W-135, and Y plain polysaccharide vaccine

Trademarks not owned by Pfizer
Menveo® (GSK Biologicals)
Menactra® (Sanofi Pasteur Inc)

Generic description
Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM <sub>197</sub> Conjugate Vaccine
Meningococcal Polysaccharide (Serogroups A, C, Y and W-135) Diphtheria Toxoid Conjugate Vaccine

## 1. INTRODUCTION

### 1.1. Background

Invasive diseases caused by *Neisseria meningitidis* are serious threats to global health. The infection rates are highly age dependent. The risk of meningococcal disease is highest in infancy, with a secondary, slightly smaller peak in late adolescence [Rosenstein, 2001]. Case-fatality rates of invasive disease are around 10% and up to 20% of patients who recover develop significant long-term sequelae [Healy, 2002]. Prevention of meningococcal disease relies on effective immunization programs. The most common serogroups are A, B, C, W-135 and Y [Harrison, 2010].

Meningococcal disease affects mostly young children with a second peak in adolescents (15-19 year age group). For those vaccinated during childhood a booster might be needed before adolescence and for those vaccinated as young adolescent's long-term antibody persistence is needed to ensure protection throughout this peak in disease incidence [Cohn, 2010]. Meningococcal vaccines are also given to travellers, including Muslim pilgrims [Mimouni, 1998; Tawfiq, 2012]. Hence there is a need to understand how long immunity persists in case of re-exposure.

It has been observed that previous meningococcal polysaccharide vaccination may influence the immune response of a meningococcal conjugate vaccine administered three years later [Keyserling, 2005; Dbaiibo, 2012a]. It is of interest to evaluate whether this phenomenon is also observed after a longer interval between the administration of the polysaccharide and the conjugate vaccine and the potential benefit of priming with a conjugate vaccine on the booster response.

Currently, there are three quadrivalent meningococcal conjugate vaccines available in various countries worldwide for vaccination of children and adolescents/adults; MenACWY diphtheria toxoid conjugate vaccine (*Menactra*, Sanofi Pasteur Inc.) is authorised for active immunization of subjects aged 9 months to 55 years in the United States (US) [Menactra Product Information, 2009; Menactra Approval Letter 2011], Canada [Menactra Product Monograph, 2012] and in the Gulf Cooperation States in the Middle East. MenACWY CRM-197 conjugate vaccine (*Menveo*, GlaxoSmithKline (GSK) Biologicals) is authorised for active immunization of subjects from 2 years of age in the European Union [Menveo Summary of Product Characteristics, 2014], from 11 years of age in Australia [Menveo Consumer Medicine Information, 2015] and from 2 months to 55 years of age in Canada and the US [Menveo Product Monograph, 2014; Menveo Highlights on Prescribing Information, 2013]. GlaxoSmithKline (GSK) Biologicals has developed a quadrivalent candidate vaccine (MenACWY-TT) for the prevention of invasive infections with *Neisseria meningitidis* serogroups A, C, Y, and W-135, using Tetanus Toxoid (TT) as the carrier. This vaccine, which was granted a marketing authorisation on 20 April 2012 by the European Commission for the active immunisation of individuals from the age of 12 months and above against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W and Y [European Commission, 2012] and is currently licensed in more than 63 countries including all European Union (EU) Member States, Iceland, Norway, Canada and

Australia. Cumulative post-marketing exposure to *Nimenrix* since launch up to April 2015 is estimated to be 1,711,167 subjects.

Pfizer completed the acquisition of *Nimenrix* and *Mencevax* on 01 October 2015, and will therefore assume responsibility of sponsor for this study.

Please refer to the current Core Data Sheet for information regarding the pre-clinical and clinical studies and the potential risks and benefits of *Nimenrix*. The Core Data Sheet is the single reference safety document (SRSD) for this study.

## 1.2. Rationale for the study and study design

Subjects aged 11-17 years of age were vaccinated with one dose of either MenACWY-TT or *Mencevax ACWY* in study MenACWY-TT-036 (109069). The participants from India and the Philippines were further followed for the assessment of persistence in study MenACWY-TT-043 (112148). Unless they withdrew their consent, subjects were invited for a yearly blood sample, regardless of their serostatus at the previous persistence time point, up to Year 5 after primary vaccination. Five years after vaccination, the percentage of subjects with rSBA titres  $\geq 1:8$  for the 4 meningococcal serogroups A, C, W-135, and Y ranged between 86.0% - 97.5% in the *Nimenrix* vaccinees and between 34.9% - 93.0% in the subjects vaccinated with *Mencevax ACWY*.

A booster dose 5 years after vaccination has already been assessed in individuals primed at the age of 11-25 years. The purpose of this study is to evaluate the safety and immunogenicity of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either a single dose of meningococcal serogroup ACWY tetanus toxoid conjugate (MenACWY-TT) vaccine or *Mencevax ACWY*. The primary vaccination study MenACWY-TT-036 (109069) was conducted in India, the Philippines and Taiwan. The MenACWY-TT-043 (112148) persistence study up to Year 5 after primary vaccination included only India and the Philippines. Due to Good Clinical Practice (GCP) issues in India, this booster study will only be conducted in the Philippines.

In order to support assay development, subjects who have voluntarily signed the informed consent document (ICD) addendum will have up to 50 mL, rather than 10 mL, of blood drawn at Visit 2.

## 1.3. Benefit : Risk Assessment

Summaries of data from pre-clinical and clinical studies conducted with MenACWY-TT, epidemiological information and the summary of potential risks and benefits can be found in the Core Data Sheet or prescribing information/product label.

### 1.3.1. Risk Assessment

The MenACWY-TT conjugate vaccine (*Nimenrix*) has demonstrated a favourable safety profile in the clinical studies performed till now.

The current section outlines the risk assessment and mitigation strategy for this study protocol. Based on the non-clinical and clinical development experience with the MenACWY-TT vaccine and post-marketing reports available at this time, there are no important identified risks associated with the MenACWY-TT vaccine. The vaccine was well tolerated without key safety findings.

The following events were assessed as potential risks associated with the MenACWY-TT vaccine based on clinical trial data or post-marketing experience:

- Cases of Guillain-Barré syndrome (GBS) have been reported in the US following administration of Menactra. Although no cases of GBS have been reported after vaccination with MenACWY-TT up to now, occurrence of GBS will be closely monitored in all studies (see Section 8.4.1). Subjects with a history of any neurological disorders or seizures, including GBS, will be excluded from participation into the study (see Section 4.3).
- Anaphylaxis may occur following exposure to allergens via immunization. Subjects who experience or have ever experienced anaphylaxis following the administration of (a) vaccine(s) will be excluded from participation into the study (see Section 4.3). Subjects will be observed closely for at least 30 minutes following the administration of the vaccine, with appropriate medical treatment readily available in case of anaphylaxis (see Section 5.6.13).
- No vaccine completely protects every vaccinated individual and a protective immune response may not be elicited in all vaccinees. Therefore, lack of efficacy will be recorded as Adverse Event (AE) as part of the safety monitoring (see Section 8.1.1).
- In the MenACWY-TT clinical development program, the MenACWY-TT vaccine was administered intramuscularly (IM). Therefore, Section 6.4 'Warnings and Precautions' of this protocol highlights that the vaccine should under no circumstances be administered intravascularly, intradermally or subcutaneously. Additionally, Section 6.4 highlights that the vaccine should be administered with caution to subjects with thrombocytopenia or a bleeding disorder as bleeding may occur following an IM administration to these subjects.
- Since tetanus toxoid has been associated with arthus type reactions and although there was limited evidence of a higher incidence of grade 3 local reactions following MenACWY-TT administration compared to *Mencevax*, extensive limb swelling and severe injection site reactions were identified as a potential risk following vaccination with MenACWY-TT. Injection site reactions will be actively solicited in this study (see Section 8.1.6).
- Due to the limited experience with the use of MenACWY-TT in pregnant women, pregnant or lactating females will be excluded from the study (see Section 4.3). Female subjects of childbearing potential are to have a urine pregnancy test prior to the study vaccine administration and will not be vaccinated if the test is positive (see Section 5.6.10).
- In addition, specific events (i.e., purpura, vasculitis, acute disseminated encephalomyelitis and brachial neuritis) have been reported following administration of meningococcal or other childhood vaccines. These events are monitored as part of

the routine pharmacovigilance plan and no specific risk minimisation is needed as part of this study.

Related to the study procedures, Section 6.4 'Warnings and Precautions' of this protocol highlights that syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to needle injection and that procedures should be in place to avoid injury from faints.

In non-clinical studies, the current formulation of the MenACWY-TT vaccine (third generation) was examined for its local reactogenicity after a single IM injection and for local and general toxicity and reactogenicity after five repeated IM injections in rabbits. A reproductive toxicology study was performed to evaluate the effect of the vaccine on embryo-fetal, pre- and post-natal development in the rat. The results of these studies indicated that the vaccine was well tolerated in animal models and no key safety findings were observed.

### 1.3.2. Benefit Assessment

In clinical studies, a single dose of MenACWY-TT was shown to have a good immunogenicity profile in toddlers [Knuf, 2010; Knuf, 2011], children aged 2-10 years [Memish, 2011; Knuf, 2010; Vesikari, 2011], adolescents [Bernal, 2011; Baxter, 2011; Østergaard, 2012] and adults [Østergaard, 2009; Dbaibo, 2012b; Ablasca-De Los Reyes, 2012; Dbaibo, 2013]. The vaccine conferred protection against invasive meningococcal diseases caused by *Neisseria meningitidis* serogroups A, C, W-135 and Y to unprimed study participants. Since the introduction of monovalent meningococcal serogroup C conjugate vaccines and the implementation of national vaccination programmes for infants and toddlers, a waning of protection following primary vaccination with MenC conjugate vaccines was observed and a booster dose in teenagers might be needed to maintain protection into adolescents [Borrow, 2013]. Several countries have already introduced booster vaccination in teenagers [Pollard, 2010]. It is also known that titres are waning over time for all serogroups [Baxter, 2011; Baxter, 2014; Baxter, 2015]. Therefore, the-primed participants of this study might also benefit from a booster dose of the study vaccine.

In addition, study participants may benefit from the medical procedures performed during the study.

### 1.3.3. Overall Benefit:Risk Conclusion

The potential risks identified in association with MenACWY-TT are justified by the anticipated benefits that may be afforded by a booster dose administered to adults primed at 11 to 17 years for protection against *Neisseria meningitidis* serogroups A, C, W-135 and Y.



## 2. OBJECTIVES

### 2.1. Primary objective

One month post-booster vaccination with MenACWY-TT vaccine in each of the study groups:

- To evaluate the immunogenicity of a booster dose of MenACWY-TT conjugate vaccine in terms of the percentage of subjects with an rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY Booster response\*.

\*Booster response to meningococcal antigens (A, C, W-135 and Y) is defined as:

- For initially seronegative subjects (pre-vaccination rSBA titer below 1:8): rSBA antibody titer  $\geq$  1:32 one month after vaccination, and
- For initially seropositive subjects (pre-vaccination rSBA titer  $\geq$  1:8): at least four-fold increase in rSBA titers from pre-vaccination to one month after vaccination.

Refer to Section 10.1 for the definition of the primary endpoint.

### 2.2. Secondary objectives

#### Secondary immunogenicity objectives:

One month post-booster vaccination with MenACWY-TT vaccine:

- To evaluate the immunogenicity of a booster dose of MenACWY-TT conjugate vaccine with respect to the percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody titers  $\geq$  1:8,  $\geq$  1:128 and Geometric Mean Titres (GMTs).

Pre-booster and one month post-booster vaccination with MenACWY-TT vaccine:

- To evaluate the percentage of subjects with anti-TT concentrations  $\geq$  0.1 IU/mL,  $\geq$  1.0 IU/mL and Geometric Mean Concentrations (GMCs).

Long-term persistence phase ten years after primary vaccination with MenACWY-TT or *Mencevax ACWY* in Study MenACWY-TT-036 (109069):

- To evaluate the long-term antibody persistence induced by MenACWY-TT conjugate vaccine as compared to *Mencevax ACWY* when administered to individuals 11-17 years of age with respect to the percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135, and rSBA-MenY antibody titers  $\geq$  1:8,  $\geq$  1:128 and GMTs.

#### Secondary safety objectives:

- To evaluate the safety and reactogenicity of a booster dose of MenACWY-TT conjugate vaccine.
- To describe Serious Adverse Events (SAEs) related to study vaccination and any event related to lack of vaccine efficacy (i.e. meningococcal disease) from the


subject's last visit in study MenACWY-TT-036 (109069) or in study MenACWY-TT-043 EXT:036 Y2, 3, 4, 5 (112148).\*

- \*last visit in study MenACWY-TT-036 (109069) will only be considered for subjects who did not participate in study MenACWY-TT-043 EXT:036 Y2, 3, 4, 5 (112148).

Refer to Section 10.2 for the definition of the secondary endpoints.

### 3. STUDY DESIGN OVERVIEW

**Figure 1 Study design diagram**



M = Month

BS = Blood Sample

Vacc = Vaccination

TC = Telephone contact

ESFU = Extended Safety Follow-Up

N = number of subjects in the primary total vaccinated cohort.

Protocol waivers or exemptions are not allowed with the exception of immediate safety concerns. Therefore, adherence to the study design requirements, including those specified in the outline of study procedures (Section 5.5), is essential and required for study conduct.

- Experimental design: Phase IIIb, open study with two parallel groups: ACWY-TT group: vaccinated with MenACWY-TT in study MenACWY-TT-036 (109069), MenPS group: vaccinated with *Mencevax ACWY* in study MenACWY-TT-036 (109069).

- Duration of the study: Approximately one month for each subject.
  - Epoch 001: Booster starting at Visit 1 (at Booster vaccination[Day 0]) and ending at Visit 2 (one month post-booster vaccination [Day 30])
- Study groups:

**Table 1 Study groups and epochs foreseen in the study**

Study Groups	Number of subjects	Age (Min - Max) (age unit)	Epoch 001
ACWY-TT	150	20 years –28 years	x
MenPS	50	20 years –28 years	x

\*The sample size of this study with respect to the analysis of immunogenicity, reactogenicity and safety post MenACWY-TT booster vaccination is driven by a) the sample size of the primary vaccination study MenACWY-TT-036 (109069) in the participating site and b) assumptions about the enrolment rate at the present extension study. For more information see Section 10.3.

**Table 2 Study groups and treatment foreseen in the study**

Treatment name	Vaccine/Product name	Study Groups	
		ACWY-TT	MenPS
MenACWY-TT	MenACWY-TT	x	x
	NaCl *	x	x

\*The lyophilized pellet of MenACWY-TT vaccine is to be reconstituted with the supplied saline solution.

- Control: uncontrolled.
- Vaccination schedule: At Visit 1 (Month 120 post primary vaccination), one dose of MenACWY-TT conjugate vaccine will be administered to all subjects in both study groups.
- Treatment allocation: The subjects in this study will be allocated to the same groups as in the vaccination study MenACWY-TT-036 (109069). Subjects will be allocated a new container number, but will retain the same subject number as in MenACWY-TT-036.
- Blinding: Study will be conducted in an open manner.

**Table 3 Blinding of study epochs**

Study Epochs	Blinding
Epoch 001	Open

- Sampling schedule: Two blood samples for each subject enrolled:
  - prior to booster vaccination,
  - one month after booster vaccination.
- Type of study: extension of other protocol(s): [MenACWY-TT-036 (109069); MenACWY-TT-043EXT:036 Y2, 3, 4 and 5 (112148)].
- Data collection: Electronic Case Report Form (eCRF).

## 4. STUDY COHORT

### 4.1. Number of subjects/centres

All subjects vaccinated with meningococcal vaccine in study MenACWY-TT-036 (109069) from the participating site in the Philippines will be considered for invitation to participate in this study. It is expected that approximately 200 subjects from the participating site in the Philippines will participate in this extension study.

Refer to Section 10.3 for the accuracy expected from the estimated sample size with respect to the primary objective.

### 4.2. Inclusion criteria for enrolment

Deviations from inclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

All subjects must satisfy ALL the following criteria at study entry:

- Subjects who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
- Written informed consent obtained from the subject prior to performing any study specific procedure.
- Healthy male or female subjects as established by medical history and history-directed physical examination before entering into the study.
- Having completed the vaccination in study MenACWY-TT-036 (109069) as per protocol.
- Female subjects of non-childbearing potential may be enrolled in the study.
  - Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral ovariectomy or post-menopause.

Please refer to the [GLOSSARY OF TERMS](#) for the definitions of menarche and post-menopause.

- Male subjects able to father children and female subjects of childbearing potential (including females who have had tubal ligation) and at risk for pregnancy may be enrolled in the study, if the subject:
  - has practiced adequate contraception for 30 days prior to vaccination, and
  - has a negative pregnancy test on the day of vaccination (for females only), and
  - has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination.

Please refer to the [GLOSSARY OF TERMS](#) for the definition of adequate contraception.

### 4.3. Exclusion criteria for enrolment

Deviations from exclusion criteria are not allowed because they can potentially jeopardize the scientific integrity of the study, regulatory acceptability or subject safety. Therefore, adherence to the criteria as specified in the protocol is essential.

The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:

- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period.
- Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose. For corticosteroids, this will be  $\geq 10$  mg/day prednisone, or equivalent. Inhaled, topical, and intra-articular steroids are allowed.
- Administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after the study vaccine dose, with the exception of a licensed inactivated influenza vaccine which can be administered at any time during the study according to the local recommendations.
- Administration of immunoglobulins and/or any blood products within the 3 months preceding the study vaccination or planned administration during the booster vaccination phase of the study (i.e. between Visit 1 and Visit 2).
- Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
- Previous vaccination with meningococcal vaccine except the meningococcal vaccination received in the MenACWY-TT-036 study.
- Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus infection, based on medical history and physical examination (no laboratory testing required).
- Family history of congenital or hereditary immunodeficiency.
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine, and history of serious allergic reaction (anaphylaxis) following the administration of vaccine(s).
- Major congenital defects or serious chronic illness.
- History of any neurological disorders or seizures, including GBS. History of a simple, single febrile seizure is permitted.
- Acute disease and/or fever at the time of vaccination.

- Fever is defined as temperature  $\geq 37.5^{\circ}\text{C}$  for oral, axillary or tympanic route, or  $\geq 38.0^{\circ}\text{C}$  for rectal route. The preferred route for recording temperature in this study will be oral.
- Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be vaccinated at the discretion of the investigator.
- Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees directly involved in the conduct of the study.
- Pregnant or lactating female.
- Female planning to become pregnant or planning to discontinue contraceptive precautions.
- Male subjects able to father children who are planning to discontinue contraceptive precautions.

## **5. CONDUCT OF THE STUDY**

### **5.1. Regulatory and ethical considerations, including the informed consent process**

The study will be conducted in accordance with all applicable regulatory requirements.

The study will be conducted in accordance with the International Conference on Harmonisation (ICH) Guideline for GCP, all applicable subject privacy requirements and the guiding principles of the Declaration of Helsinki (World Medical Association 1996 & 2008) as well as the general principles set forth in the International Ethical Guidelines for Biomedical Research Involving Human Subjects (Council for International Organizations of Medical Sciences 2002).

The study has been designed and will be conducted in accordance with the ICH Harmonised Tripartite Guideline for clinical investigation of medicinal products and all other applicable ethical guidelines.

Pfizer will obtain favourable opinion/approval to conduct the study from the appropriate regulatory agency, in accordance with applicable regulatory requirements.

Conduct of the study includes, but is not limited to, the following:

- Institutional Review Board (IRB)/Independent Ethics Committee (IEC) review and favourable opinion/approval of study protocol and any subsequent amendments.
- Subject informed consent.
- Investigator reporting requirements as stated in the protocol.

Pfizer will provide full details of the above procedures to the investigator, either verbally, in writing, or both.

Freely given and written informed consent must be obtained from each subject prior to participation in the study.

Pfizer will prepare a model Informed Consent Form (ICF) which will embody the ICH GCP and Pfizer required elements. While it is strongly recommended that this model ICF is to be followed as closely as possible, the informed consent requirements given in this document are not intended to pre-empt any local regulations which require additional information to be disclosed for informed consent to be legally effective. Clinical judgement, local regulations and requirements should guide the final structure and content of the local version of the ICF.

In accordance with the ICH Harmonised Tripartite Guidelines for Good Clinical Practice, those subjects who can only be enrolled in the study with the consent of the subject's legally acceptable representative (e.g., minors), should be informed about the study to the extent compatible with the subject's understanding and, if capable, the subject should sign and personally date a written informed assent form (IAF). It is required that the assent be signed by each subject, if capable, in addition to the informed consent that is to be signed by his/her legal representative. It should be assessed whether an assent is required depending of the age of the study population and the local requirements.

If the subject reaches the age of consent during the study, he/she will be asked to provide consent at the next study visit (if applicable). This procedure should be applied according to local laws and regulations.

The investigator has the final responsibility for the final presentation of the ICF, respecting the mandatory requirements of local regulations. The ICF generated by the investigator with the assistance of the sponsor's representative must be acceptable to Pfizer and be approved (along with the protocol, and any other necessary documentation) by the IRB/IEC.

## **5.2. Subject identification and randomisation of treatment**

### **5.2.1. Subject identification**

Approximately 200 subjects are expected to participate in this study (150 from the ACWY-TT group and 50 from the MenPS group). Subjects will retain the same subject number as in MenACWY-TT-036 (109069).

#### **5.2.1.1. Treatment allocation to the subject**

The container numbers will be allocated by booster dose administered.

##### **5.2.1.1.1. Study group and container number allocation**

Subjects who received either MenACWY-TT or *Mencevax ACWY* vaccine in study MenACWY-TT-036 will be invited to participate in this study and will be eligible for this

study if they meet the inclusion/exclusion criteria. Approximately 200 subjects are expected to participate in the study.

There will be no randomisation for allocation to study groups in this study. The subjects in this study will be allocated to the same groups as in the vaccination study MenACWY-TT-036 (109069). Subjects will be allocated a new container number.

Allocation of subjects to vaccine groups will proceed through the use of an interactive response technology (IRT) system. The site personnel (study coordinator or specified designee) will be required to enter or select information including but not limited to the user's identification (ID) and password, the protocol number, the subject number and the date of birth of the subject. The site personnel will then be provided with a vaccine assignment and dispensable unit (DU) or container number. The IRT system will provide a confirmation report containing the subject number and DU or container number assigned.

After obtaining the signed and dated ICF from the subject and having checked the eligibility of the subject, the site staff in charge of the vaccine administration will access IRT. Upon providing the subject identification number, the randomisation system will determine the study group and will provide the container number to be used for the dose.

The number of each administered treatment must be recorded in the eCRF on the Vaccine Administration screen.

When IRT is not available, please refer to the IRT user guide or the Study Procedures Manual (SPM) for specific instructions.

### **5.3. Method of blinding**

This study will be conducted in an open manner.

### **5.4. General study aspects**

Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying SPM. The SPM provides the investigator and the site personnel with administrative and detailed technical information that does not impact the safety of the subjects.



## 5.5. Outline of study procedures

See Table 4 for the list of study procedures.

**Table 4 List of study procedures**

Epoch	Epoch 001	
Visit	VISIT 1*	VISIT 2
Timing	Month 120 (10 years post- primary vaccination)	Month 121
Sampling time point	Pre-booster vaccination	One month-post booster vaccination
Informed consent	●	● <sup>1</sup>
Demography	●	
Check inclusion/exclusion criteria	●	
Check contraindications	○	
Check warnings and precautions	○	
Check general medical history	● <sup>†</sup>	
Meningococcal vaccination history	● <sup>‡</sup>	
Recording of last TT vaccination date	●	
History-directed physical examination	●	
Pre-vaccination assessment of body temperature	●	
Pre-vaccination assessment of contraception (see section 4.2)	○	
Urine pregnancy test for females	●	
Blood sampling: for antibody determination (approximately 10 mL)	●	● <sup>2</sup>
Record timing related to reconstitution and vaccination	●	
Vaccination (MenACWY-TT)	●	
Record container number	●	
Observation of subjects for 30 minutes post vaccination	○	
Daily post-vaccination recording by subjects, of solicited adverse events within 4 days (Days 0-3) after administration of the booster dose	●	
Recording by subjects, of non-Serious Adverse Events (SAE) Days 0-30 post-vaccination	●	●
Return of diary cards <sup>3</sup>		○
Diary card transcription		○
Record any concomitant medication/vaccination <sup>4</sup>	●	●
Record any intercurrent medical conditions <sup>5</sup>	●	●
Reporting of all SAEs <sup>6</sup>	●	●
Recording of SAEs related to study vaccination and any event related to lack of vaccine efficacy since the previous visit <sup>6,7</sup>	●	●
Recording of SAEs related to study participation	●	●
Reporting of New Onset of Chronic Illness (NOCI) <sup>8,10</sup>	●	●
Reporting of Guillain Barré Syndrome (GBS) <sup>9,10</sup>	●	●
Reporting of Pregnancies <sup>11</sup>	●	●
Study Conclusion		● <sup>12</sup>

● is used to indicate a study procedure that requires documentation in the individual eCRF.

○ is used to indicate a study procedure that does not require documentation in the individual CRF/eCRF.

\*The subject will be contacted by phone approximately 4-8 weeks beforehand to come in for the first visit

<sup>†</sup>It is important to collect and document in the eCRF a complete assessment of the medical history for all subjects at Visit 1. Record all medical conditions/signs/symptoms current or past at the time of visit 1.

‡ At the subject's first visit in the current study, medical and meningococcal vaccination history since the subject's last visit done in the study MenACWY-TT-036 (109069) or in the study MENACWY-TT-043 EXT:036 Y2, 3, 4, 5 (112148).

<sup>1</sup> If the subject agrees to have up to 50 mL of blood drawn at Visit 2, he or she must sign the addendum to the consent form before the sample is taken. This consent can be signed at Visit 1.

<sup>2</sup> Subjects who have consented will have up to 50 mL of blood drawn at Visit 2.

<sup>3</sup> If the subject returns for Visit 2 prior to Day 30, the subject should take home the diary card, continue to record unsolicited safety information until Day 30 and then provide the card to the study site.

<sup>4</sup> See Section 6.5.2 for medications and timeframe for reporting.

<sup>5</sup> These conditions include: Any confirmed or suspected condition that has the capability of altering the subject's immune response (e.g. intercurrent lymphopenia, any confirmed or suspected immunosuppressive or immunodeficient condition and diagnosis of serious chronic illness) throughout the study.

<sup>6</sup> Occurrence of meningococcal diseases should be documented on the SAE report and in the eCRF.

<sup>7</sup> At the subject's first visit in the current study, SAEs experienced since the subject's last visit in the persistence study MENACWY- TT-043 EXT:036 Y2, 3, 4, 5 (112148) should also be recorded. For subjects not enrolled in the MENACWY- TT-043 EXT:036 Y2, 3, 4, 5 (112148) study, the recording will be done since the subject's last visit in the MenACWY-TT-036 (109069) study.

<sup>8</sup> NOCIs (e.g. auto-immune disorders, allergies, type 1 diabetes, asthma) will be recorded within 31 days from booster vaccination (Day 30) with day of booster vaccination considered Day 0. NOCIs will be reported as unsolicited AEs or SAEs as appropriate. A non-exhaustive list of NOCIs is provided in Table 13.

<sup>9</sup> In the event of GBS, subjects should be contacted to obtain clinical details as outlined in the 'potential immune mediated disorders: standard questionnaires and list of preferred terms'. All occurrences of GBS have to be reported as an SAE.

<sup>10</sup> Recording will start after administration of the booster vaccination (Day 0) and ending 31 days from booster vaccination (Day 30).

<sup>11</sup> Pregnancies occurring between vaccination (Day 0) and 31 days from vaccination (Day 30) will be recorded. If, after having been vaccinated, a subject is found to have been pregnant at vaccination, the pregnancy will be recorded as an exclusion criterion.

<sup>12</sup> To be completed for all subjects who are enrolled in the study.

It is the investigator's responsibility to ensure that the intervals between visits/contacts are strictly followed. These intervals determine each subject's evaluability in the According-To-Protocol (ATP) analyses.

Table 5 presents the intervals between study visits.

**Table 5 Intervals between study visits**

Interval	Optimal length of interval <sup>1</sup>	Allowed interval <sup>2</sup>
Primary vaccination→Visit 1	520 weeks	520 ± 26 weeks
Visit 1→Visit 2	30 days	21-48 days <sup>3</sup>

<sup>1</sup> Whenever possible the investigator should arrange study visits within this interval.

<sup>2</sup> Subjects will not be eligible for inclusion in the ATP cohort for immunogenicity if they make the study visit outside this interval (see Section 10.4 for the definition of the study cohorts).

<sup>3</sup> For the safety evaluation an interval of 30 days is needed. If the subject returns for Visit 2 prior to Day 30, the subject should take home the diary card, continue to record unsolicited safety information until Day 30 and then provide the card to the study site.

## 5.6. Detailed description of study procedures

### 5.6.1. Informed consent

The signed informed consent of the subject must be obtained before study participation. Refer to Section 5.1 for the requirements on how to obtain informed consent. If the

subject agrees to have up to 50 mL of blood drawn at Visit 2, he or she must sign the ICD addendum before the sample is taken.

Signing of ICF will be recorded in the eCRF.

#### **5.6.2. Check inclusion and exclusion criteria**

Check all inclusion and exclusion criteria as described in Sections 4.2 and 4.3 before enrolment.

#### **5.6.3. Collect demographic data**

Record demographic data such as partial date of birth (month and year) and gender in the subject's eCRF.

#### **5.6.4. Check contraindications, warnings and precautions to vaccination**

Contraindications, warnings and precautions to vaccination must be checked at the beginning of the vaccination visit. Refer to Section 6.4 for more details.

#### **5.6.5. Medical history**

Obtain the subject's medical history by interview and/or review of the subject's medical records and record any pre-existing conditions or signs and/or symptoms present in a subject prior to the study vaccination in the eCRF.

#### **5.6.6. Recording of meningococcal and TT vaccination history**

Record the history of meningococcal vaccination and the last TT vaccination date in the eCRF.

#### **5.6.7. History directed physical examination**

Perform a history directed physical examination. If the investigator determines that the subject's health on the day of vaccination temporarily precludes vaccination, the visit will be rescheduled. Collected information needs to be recorded in the eCRF.

Treatment of any abnormality observed during this examination has to be performed according to local medical practice outside this study or by referral to an appropriate health care provider.

#### **5.6.8. Assess pre-vaccination body temperature**

The axillary, rectal, oral or tympanic body temperature of all subjects needs to be measured prior to any study vaccine administration. The preferred route for recording temperature in this study will be oral. If the subject has fever (fever is defined as temperature  $\geq 37.5^{\circ}\text{C}$  for oral, axillary or tympanic route, or  $\geq 38.0^{\circ}\text{C}$  for rectal route) on

the day of vaccination, the vaccination visit will be rescheduled within the allowed interval for this visit (see [Table 5](#)).

#### **5.6.9. Pre-Vaccination assessment of contraception**

The investigator or his/her designee will discuss with the subject the need to use adequate contraception consistently and correctly according to the glossary of terms (and outline of study procedures) and document such conversation in the subject's medical records. In addition, the investigator or his/her designee will instruct the subject to call immediately if the selected contraception method is discontinued or if pregnancy is known or suspected in the subject or the subject's partner.

#### **5.6.10. Urine pregnancy test**

For female subjects of childbearing potential, a urine pregnancy test, with sensitivity of at least 25 mIU/mL, will be performed immediately before administration of the vaccine dose. A negative pregnancy test result is required before the subject may receive the study vaccine. In the case of a positive confirmed pregnancy, the subject will be withdrawn from administration of study vaccine but may remain in the study. Pregnancy tests may also be repeated as per request of institutional review boards (IRBs)/ethics committees (ECs) or if required by local regulations.

Note: The urine pregnancy test must be performed even if the subject is menstruating at the time of the study visit.

#### **5.6.11. Container number allocation**

Container number allocation will be performed as described in Section [5.2.1.1.1](#). The number of each administered container must be recorded in the eCRF.

#### **5.6.12. Sampling**

Refer to the Module on Biospecimen Management in the SPM for detailed instructions for the collection, handling and processing of the samples.

##### **5.6.12.1. Blood sampling for safety or immune response assessments**

Blood samples will be taken during the two study visits as specified in Section [5.5](#) List of Study Procedures.

- A volume of approximately 10 mL of whole blood (to provide approximately 5 mL of serum) should be drawn by venipuncture from all subjects at each visit. Alternatively, subjects who signed the ICD addendum will have up to 50 mL of whole blood drawn at Visit 2. After centrifugation, serum samples should be kept at -20°C or below until shipment. Refer to the SPM for more details on sample storage conditions.

**5.6.13. Study Vaccine administration**

- Study vaccine will be administered at Visit 1. After completing all prerequisite procedures prior to vaccination, one dose of study vaccine will be administered IM preferably in the deltoid of the non-dominant arm (refer to Section 6.3 for a detailed description of the vaccine administration procedure). If the investigator or delegate determines that the subject's health on the day of administration temporarily precludes vaccine administration, the visit will be rescheduled within the allowed interval for this visit (refer to Table 5).
- The time of reconstitution and administration of the vaccine will be recorded.
- The subjects will be observed closely for at least 30 minutes following the administration of the vaccine, with appropriate medical treatment readily available in case of anaphylaxis.

**5.6.14. Check and record concomitant medication/vaccination and intercurrent medical conditions**

Concomitant medication/vaccination must be checked and recorded in the eCRF as described in Section 6.5

Intercurrent medical conditions must be checked and recorded in the eCRF as described in Section 6.6.

**5.6.15. Recording of AEs, SAEs and pregnancies**

- Refer to Section 8.2 for procedures for the investigator to record AEs, SAEs and pregnancies. Refer to Section 8.3 for guidelines and how to report SAEs and Exposure During Pregnancy (EDP) reports to Pfizer.
- The subjects will be instructed to contact the investigator immediately should they manifest any signs or symptoms they perceive as serious.
- After the vaccination visit, diary cards will be provided to the subject. The subject will record body (oral) temperature and any solicited local/general AEs (i.e. on the day of vaccination and during the next 3 days) or any unsolicited AEs (i.e. on the day of vaccination and during one month [the next 30 days]) after vaccination. The subject will be instructed to return the completed diary card to the investigator at the next study visit.
- Collect and verify completed diary cards during discussion with the subject at Visit 2 (scheduled one month [30 days] after the vaccine dose). If the subject returns for Visit 2 prior to one month [Day 30], the subject should take home the diary card, continue to record unsolicited safety information until one month [Day 30] and then provide the card to the study site.
- Any unreturned diary cards will be sought from the subject through telephone call(s) or any other convenient procedure. The investigator will transcribe the collected information into the eCRF in English.

**5.6.15.1. Recording of GBS and New Onset of Chronic Illnesses (NOCIs)**

- Please refer to Section 8.2 for procedures for the investigator to record GBS and NOCIs. Refer to Section 8.3 for guidelines on how to report GBS and NOCIs.
- In the event of GBS, subjects should be contacted to obtain clinical details as outlined in the 'potential immune mediated disorders: standard questionnaires and list of preferred term'. All occurrences of GBS have to be reported as SAE(s).
- NOCIs (e.g. auto-immune disorders, asthma, type 1 diabetes, allergies) will be reported as unsolicited AEs or SAE as appropriate.

**5.6.16. Study conclusion**

The investigator will:

- review data collected to ensure accuracy and completeness,
- complete the Study Conclusion screen in the eCRF.

**5.7. Biological sample handling and analysis**

Refer to the SPM for details on biospecimen management (handling, storage and shipment). See section 5.6.12.1 for a brief description of the procedure for collection, preparation, and storage of serum samples.

Samples will not be labelled with information that directly identifies the subject but will be coded with the identification number for the subject (subject number).

- Collected samples will be used for protocol mandated research and purposes related to the improvement, development and quality assurance of the laboratory tests described in this protocol. This may include the management of the quality of these tests, the maintenance or improvement of these tests, the development of new test methods, as well as making sure that new tests are comparable to previous methods and work reliably.
- It is also possible that future findings may make it desirable to use the samples acquired in this study for future research, not described in this protocol. Therefore, all subjects in countries where this is allowed, will be asked to give a specific consent to allow Pfizer or a contracted partner to use the samples for future research. Future research will be subject to the laws and regulations in the respective countries and will only be performed once an IEC or Review Board has approved this research.

Information on further investigations and their rationale can be obtained from Pfizer.

Any sample testing will be done in line with the consent of the individual subject.

Refer also to the [Investigator Agreement](#), where it is noted that the investigator cannot perform any other biological assays except those described in the protocol or its amendment(s).

If additional testing is performed, the marker priority ranking given in Section 5.7.4 may be changed.

Collected samples will be stored for a maximum of 15 years (counting from when the last subject performed the last study visit), unless local rules, regulations or guidelines require different timeframes or different procedures, which will then be in line with the subject consent. These extra requirements need to be communicated formally to and discussed and agreed with Pfizer.

### 5.7.1. Use of specified study materials

When materials are provided by Pfizer or designee, it is MANDATORY that all clinical samples (including serum samples) be collected and stored exclusively using those materials in the appropriate manner. The use of other materials could result in the exclusion of the subject from the ATP analysis (See Section 11.5 for the definition of study cohorts/ data sets to be analysed). The investigator must ensure that his/her personnel and the laboratory(ies) under his/her supervision comply with this requirement. Refer to the Module on Clinical Trial Supplies in the SPM.

### 5.7.2. Biological samples

The sample type, quantity and time point for blood draws for the ACWY-TT and MenPS groups is shown in Table 6.

**Table 6 Biological samples for the ACWY-TT and MenPS groups**

Sample type	Quantity	Unit	Time points
Blood	Approximately 10	mL	Visit 1 (pre-booster), Visit 2 (post-booster)
Blood	Up to 50 (voluntary subjects)	mL	Visit 2 (post-booster)*

\*In order to support assay development, subjects who signed the ICD addendum will have up to 50 mL, rather than 10 mL, of blood drawn at Visit 2.

### 5.7.3. Laboratory assays

Please refer to [APPENDIX A](#) for a detailed description of the assays performed in the study. Please refer to [APPENDIX B](#) for the address of the clinical laboratories used for sample analysis.

Serological assays will be performed at Public Health England (PHE; Manchester, UK) using standardised and validated procedures (refer to [Table 7](#)).

See [Table 7](#) for details of the laboratory assays.



**Table 7 Humoral Immunity (Antibody determination)**

Component	Method	Test kit/ Manufacturer	Unit	Cut-off	Laboratory
Neisseria meningitidis Serogroup A L10 3125 Ab	rSBA	NA	1/DIL	8	PHE*
Neisseria meningitidis Serogroup C L3v C11 Ab	rSBA	NA	1/DIL	8	PHE*
Neisseria meningitidis Serogroup W L3v MP01240070 Ab	rSBA	NA	1/DIL	8	PHE*
Neisseria meningitidis Serogroup Y L3v S1975 Ab	rSBA	NA	1/DIL	8	PHE*
Clostridium tetani.Tetanus Toxoid Ab.IgG	dLIA**	NA	IU/mL	0.1	***PPD

rSBA = Serum Bactericidal Assay (using baby rabbit complement)

1/DIL = Dilution for at least 50% killing

\*PHE = Public Health England (previously the Health Protection Agency [HPA])

\*\*dLIA – Direct Luminex Immunoassay

\*\*\*PPD – Pharamceutical Product Development, Inc. Bioanalytical Laboratories

#### 5.7.4. Biological samples evaluation

##### 5.7.4.1. Immunological read-outs

Table 8 provides the immunological read-outs.

**Table 8 Immunological read-outs**

Blood sampling time point		No. subjects	Component	Components priority rank
Type of contact and time point	Sampling time point			
Visit 1 (Month120)	Pre-booster vaccination	200	rSBA-MenA, rSBA-MenW-135, rSBA-MenY, rSBA-MenC, anti-TT	rSBA-MenC > rSBA-MenA > rSBA-MenW-135 > rSBA-MenY > anti-TT
Visit 2 (Month121)	One month-post booster vaccination	180	rSBA-MenA, rSBA-MenW-135, rSBA-MenY, rSBA-MenC, anti-TT	rSBA-MenC > rSBA-MenA > rSBA-MenW-135 > rSBA-MenY > anti-TT

In case of insufficient blood sample volume to perform assays for all antibodies, the samples will be analysed according to priority ranking provided in Table 8.

#### 5.7.5. Immunological correlates of protection

Bactericidal assay using rabbit complement (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY):

Bactericidal antibodies are recognized as surrogate markers of protection. The use of 1:8 and 1:128 as rSBA endpoints when using rabbit complement for rSBA-MenC has been discussed at a recent World Health Organisation (WHO) conference [WHO, 2011].

Effectiveness data in the United Kingdom have further validated rSBA-MenC  $\geq$  1:8 as protective [Andrews, 2003]. The threshold for protection for other serogroups is still to be defined, although it is common practice to extend the 1:8 cut-off to rSBA-MenA, rSBA-MenW-135 and rSBA-MenY [WHO, 2011]. For meningococcal (unconjugated)



PSs, a 4-fold increase in SBA titres from pre-vaccination to post-vaccination is commonly accepted as a marker of immunogenicity [[Anonymous](#), 1999; [WHO](#), 1981].

Antibodies against tetanus toxoid (Anti-TT):

Tetanus toxoid antibody concentrations greater than or equal to 0.1 IU/mL are considered as protective [[McComb](#), 1964; [Newell](#), 1971]. The direct Luminex immunoassay (dLIA) lower limit of quantitation (LLOQ) for tetanus toxoid based on Pfizer's validation is 0.05 IU/mL at 1:1000 dilution. Based on this value, a dLIA result of <0.1 IU/mL is considered a negative clinical response and a dLIA result  $\geq 0.1$  IU/mL is considered a positive clinical response.

### **Communication of individual immunological assay results to study investigator**

Where a generally accepted correlate of protection exists, individual immunological assay results for the subjects identified as non-responders (i.e., antibody level below the established correlate of protection one month after vaccination) could be defined using the following threshold.

- rSBA-MenC antibody titer < 1:8
- tetanus toxoid antibody titers < 0.1 IU/mL

Although no correlate of protection is established for *N. meningitidis* serogroups A, W-135 and Y, individual immunology assay results for these 3 antigens will also be provided to the study investigator.

The immunological assay results will be communicated to the investigators.

For the study subjects identified as non-responders, it remains the responsibility of the study investigator in charge of the subject's clinical management to determine the medical need for re-vaccination and to re-vaccinate the subjects as per local/regional practices.

## **6. STUDY VACCINE AND ADMINISTRATION**

### **6.1. Description of study vaccine**

The vaccine (MenACWY-TT) to be used in this study was acquired by Pfizer on 01 October 2015.

The vaccine is labelled and packed according to applicable regulatory requirements.

[Table 9](#) presents the description of the study vaccine.

**Table 9 Study vaccine**

Treatment name	Vaccine/ product name	Formulation	Presentation	Volume to be administered	Number of doses
MenACWY-TT	MenACWY-TT *	PSA=5µg TT; PSC=5µg TT; PSW <sub>135</sub> =5µg TT; PsY=5µg TT; TT~44µg Tris- HCL, pH 6.8 ± 0.3 1.6 mM; Sucrose 28 mg	Lyophilized pellet to be reconstituted with saline diluent	0.5 mL	1
	NaCl	NaCl=150mM	liquid		

\*The lyophilized pellet of MenACWY-TT vaccine is to be reconstituted with the supplied saline solution.

## 6.2. Storage and handling of study vaccine

The study vaccine will be shipped at +2°C to +8°C to each study site upon request. Upon receipt at the study site, the vaccine should be immediately transferred to a +2°C to +8°C temperature-monitored refrigerator for storage. Storage conditions stated in the SRSD (ie, CDS) may be superseded by the storage conditions stated in the labeling.

The study vaccine must be stored in a safe and locked place. Access to the storage space should be limited to authorized study personnel. The storage conditions will be assessed during pre-study activities under the responsibility of the sponsor study contact. The storage temperature should be continuously monitored with calibrated (if not validated) temperature monitoring device(s) and recorded. Refer to the Module on Clinical Trial Supplies in the SPM for more details on storage of the study vaccine.

Temperature excursions must be reported in degree Celsius.

Refer to the Module on Clinical Trial Supplies in the SPM for details and instructions on the temperature excursion reporting and usage decision process, packaging and accountability of the study vaccine.

Any excursions from the product label storage conditions should be reported upon discovery. The site should actively pursue options for returning the product to the storage conditions as described in the labeling, as soon as possible. Deviations from the storage requirements, including any actions taken, must be documented and reported to the sponsor. Once an excursion is identified, the study vaccine must be quarantined and not used until the sponsor provides documentation of permission to use the study vaccine. It will not be considered a protocol deviation if the sponsor approves the use of the study vaccine after the temperature excursion. Use of the study vaccine prior to sponsor approval will be considered a protocol deviation.

Specific details regarding information the site should report for each excursion will be provided to the site.

### 6.3. Dosage and administration of study vaccine

**Table 10 Dosage and administration**

Type of contact and time point	Volume to be administered	Study Group	Treatment name	Route <sup>1</sup>	Site	Side <sup>2</sup>
Visit 1 (Month120)	0.5 mL	ACWY-TT	MenACWY-TT	IM	Deltoid	Left or Right
	0.5 mL	MenPS	MenACWY-TT	IM	Deltoid	Left or Right

<sup>1</sup>Intramuscular (IM)

<sup>2</sup>Preferably the non-dominant side

#### Reconstitution of the MenACWY-TT vaccine

The lyophilized white pellet of MenACWY-TT vaccine is to be reconstituted with the supplied saline solution to obtain 0.5 mL for administration. The vaccine reconstitution will be described in detail in the Core Data Sheet.

#### Injection technique

A needle of at least 25 mm (1 inch), 22-25 gauge should be used for injection in the deltoid muscle.

The following injection technique is recommended:

- Use of aseptic technique with reconstitution and delivery of injection
- To avoid injection into subcutaneous tissue, spread the skin of the selected vaccine administration site taut between the thumb and forefinger, isolating the muscle.
- Insert the needle fully into the muscle at a 90° angle and inject the vaccine into the tissue.
- Withdraw the needle and apply light pressure to the injection site for several seconds with a dry cotton ball or gauze.

### 6.4. Warnings and precautions

MenACWY-TT should under no circumstances be administered intravascularly, intradermally or subcutaneously.

MenACWY-TT should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an IM administration to these subjects.

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.

## 6.5. Concomitant medication/product and concomitant vaccination

At each study visit/contact, the investigator should question the subject about any medications/products taken and vaccinations received by the subject.

### 6.5.1. Recording of concomitant medications/products and concomitant vaccination

The following concomitant medications/products/vaccines must be recorded in the eCRF if administered during the indicated recording period:

- Any concomitant medications/products/vaccines listed in Section 6.5.2.
- All concomitant medications/products, except vitamins and dietary supplements, administered 30 days following the booster dose of study vaccine.
- Any concomitant vaccination administered in the period starting 30 days before the booster dose of study vaccine and ending at the last study visit.
- Prophylactic medication (i.e. medication administered in the absence of ANY symptom and in anticipation of a reaction to the vaccination) from just prior to vaccination up to Visit 2.

E.g. an anti-pyretic is considered to be prophylactic when it is given in the absence of fever and any other symptom, to prevent fever from occurring [fever is defined as temperature  $\geq 37.5^{\circ}\text{C}$  for oral, axillary or tympanic route, or  $\geq 38.0^{\circ}\text{C}$  for rectal route].

- Any concomitant medications/products/vaccines relevant to a SAE\* or administered at any time during the study period for the treatment of a SAE\*. In addition, concomitant medications relevant to SAEs need to be recorded on the Serious Adverse Event Report Form.

\* SAEs that are required to be reported per protocol.

### 6.5.2. Concomitant medications/products/vaccines that may lead to the elimination of a subject from ATP analyses

The use of the following concomitant medications/products/vaccines will not require withdrawal of the subject from the study but may determine a subject's evaluability in the ATP analysis. See Section 10.4 for cohorts to be analysed.

- Any investigational or non-registered product (drug or vaccine) other than the study vaccine used during the study period.
- Immunosuppressants or other immune-modifying drugs administered chronically (i.e. more than 14 days in total) during the study period. For corticosteroids, this will mean prednisone  $\geq 0.5$  mg/kg/day with an upper limit of 10 mg/day or equivalent. Inhaled, topical, and intra-articular steroids are allowed.

- A vaccine not foreseen by the study protocol administered during the period starting 30 days before the booster dose of vaccine and ending 30 days after\*, with the exception of inactivated influenza vaccine which can be administered at any time during the study according to the local recommendations.

\*In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is organised by the public health authorities, outside the routine immunisation program, the time period described above can be reduced if necessary for that vaccine provided it is licensed and used according to its summary of product characteristics or product information and according to the local governmental recommendations.

- Administration of a meningococcal vaccine not foreseen by the study protocol at any time during the study period.
- Immunoglobulins and/or any blood products administered within the 3 months preceding the study vaccination or planned administration during the study (i.e. between Visit 1 and Visit 2).

A detailed, comprehensive list of reasons for elimination from ATP analyses will be established at the time of data cleaning.

## **6.6. Intercurrent medical conditions that may lead to elimination of a subject from ATP analyses**

At each study visit it must be verified if the subject has experienced or is experiencing any intercurrent medical condition. If it is the case, the condition(s) must be recorded in the eCRF.

The following may result in the elimination of subjects from the ATP cohort for immunogenicity, but not necessarily from the study:

- Occurrence of meningococcal disease\*.
- Any confirmed or suspected condition that has the capability of altering the subject's immune response (e.g. intercurrent lymphopenia)
- Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination (no laboratory testing required)

\* Occurrence of meningococcal disease should be reported as an SAE.

## **7. HEALTH ECONOMICS**

Not applicable

## **8. SAFETY**

The investigator or site staff is/are responsible for the detection, documentation and reporting of events meeting the criteria and definition of an AE or SAE as provided in this protocol.

Each subject will be instructed to contact the investigator immediately should they manifest any signs or symptoms they perceive as serious.

## **8.1. Safety definitions**

### **8.1.1. Definition of an adverse event**

An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse.

Examples of an AE include:

- Significant or unexpected worsening or exacerbation of the condition/indication under study.
- Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition.
- New conditions detected or diagnosed after investigational vaccine administration even though they may have been present prior to the start of the study.
- Signs, symptoms, or the clinical sequelae of a suspected interaction.
- Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational vaccine or a concurrent medication (overdose per se should not be reported as an AE/SAE).
- Signs, symptoms temporally associated with vaccine administration.
- Pre- or post-treatment events that occur as a result of protocol-mandated procedures (i.e. invasive procedures, modification of subject's previous therapeutic regimen).
- Medication errors.
- Occupational exposure.

AEs to be recorded as endpoints (solicited AEs) are described in Section 10.2. All other AEs will be recorded as UNSOLICITED AEs.

Examples of an AE DO NOT include:

- Medical or surgical procedures (e.g. endoscopy, appendectomy); the condition that leads to the procedure is an AE/SAE.
- Situations where an untoward medical occurrence did not occur (e.g. social and/or convenience admission to a hospital, admission for routine examination).

- Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen.
- Pre-existing conditions or signs and/or symptoms present in a subject prior to the first study vaccination. These events will be recorded in the medical history section of the eCRF.

### 8.1.2. Medication Errors

Medication errors may result, in this study, from the administration or consumption of the wrong product, by the wrong subject, at the wrong time, or at the wrong dosage strength. Such medication errors occurring to a study participant are to be captured on the medication error CRF, which is a specific version of the AE page, and on the SAE form when appropriate. In the event of medication dosing error, the sponsor should be notified immediately.

Medication errors are reportable irrespective of the presence of an associated AE/SAE, including:

- Medication errors involving subject exposure to the study vaccine;
- Potential medication errors or uses outside of what is foreseen in the protocol that do or do not involve the participating subject.

Whether or not the medication error is accompanied by an AE, as determined by the investigator, the medication error is captured on the medication error version of the AE page and, if applicable, any associated AE(s) are captured on an AE CRF page.

Other examples include, but are not limited to:

- The administration of expired study vaccine;
- The administration of an incorrect study vaccine;
- The administration of an incorrect dosage;
- The administration of study vaccine that has undergone temperature excursion from the specified storage range, unless it is determined by the sponsor that the study vaccine under question is acceptable for use.

### 8.1.3. Occupational Exposure

An occupational exposure occurs when, during the performance of job duties, a person (whether a healthcare professional or otherwise) gets in unplanned direct contact with the product, which may or may not lead to the occurrence of an AE.

An occupational exposure is reported to the drug safety unit within 24 hours of the investigator's awareness, using the SAE report form, regardless of whether there is an associated AE/SAE. Since the information does not pertain to a subject enrolled in the

study, the information is not reported on a CRF; however, a copy of the completed SAE report form is maintained in the investigator site file.

#### 8.1.4. Exposure During Pregnancy

For both unapproved/unlicensed products and for marketed products, an exposure during pregnancy (EDP) occurs if:

1. A female becomes, or is found to be, pregnant either while receiving or having been exposed (eg, because of treatment or environmental exposure) to the study vaccine; or the female becomes or is found to be pregnant after discontinuing and/or being exposed to the study vaccine;
2. An example of environmental exposure would be a case involving direct contact with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has been exposed to chemotherapeutic products).
3. A male has been exposed (eg, because of treatment or environmental exposure) to the study vaccine prior to or around the time of conception and/or is exposed during his partner's pregnancy.

If a study subject or study subject's partner becomes or is found to be pregnant during the study subject's treatment with the study vaccine, the investigator must submit this information to the Pfizer drug safety unit on an SAE report form and an EDP supplemental form, regardless of whether an SAE has occurred. In addition, the investigator must submit information regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject reports that she is pregnant and has been exposed to a cytotoxic product by inhalation or spillage) using the EDP supplemental form. This must be done irrespective of whether an AE has occurred and within 24 hours of awareness of the exposure. The information submitted should include the anticipated date of delivery (see below for information related to termination of pregnancy).

Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP reports with an unknown outcome. The investigator will follow the pregnancy until completion (or until pregnancy termination) and notify Pfizer of the outcome as a follow-up to the initial EDP supplemental form. In the case of a live birth, the structural integrity of the neonate can be assessed at the time of birth. In the event of a termination, the reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by gross visual inspection (unless preprocedure test findings are conclusive for a congenital anomaly and the findings are reported).

If the outcome of the pregnancy meets the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomaly [in a live-born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the investigator should follow the procedures for reporting SAEs.

Additional information about pregnancy outcomes that are reported as SAEs follows:



- Spontaneous abortion includes miscarriage and missed abortion;
- Neonatal deaths that occur within 1 month of birth should be reported, without regard to causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs when the investigator assesses the infant death as related or possibly related to exposure to the study vaccine.

Additional information regarding the EDP may be requested by the investigator. Further follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the study subject with the Pregnant Partner Release of Information Form to deliver to his partner. The investigator must document in the source documents that the subject was given the Pregnant Partner Release of Information Form to provide to his partner.

### 8.1.5. Definition of a serious adverse event

A serious adverse event is any untoward medical occurrence that:

- Results in death,
- Is life-threatening,

Note: The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, had it been more severe.

- Requires hospitalisation or prolongation of existing hospitalisation,

Note: In general, hospitalisation signifies that the subject has been admitted at the hospital or emergency ward for observation and/or treatment that would not have been appropriate in the physician’s office or in an out-patient setting. Complications that occur during hospitalisation are also considered AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event will also be considered serious. When in doubt as to whether ‘hospitalisation’ occurred or was necessary, the AE should be considered serious.

Hospitalisation for elective treatment of a pre-existing condition (known or diagnosed prior to informed consent signature) that did not worsen from baseline is NOT considered an AE.

- Results in disability/incapacity,

Note: The term disability means a substantial disruption of a person’s ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza like illness, and accidental trauma (e.g. sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.

- Is a congenital anomaly/birth defect in the offspring of a study subject, OR

f. Lack of efficacy.

Medical or scientific judgement should be exercised in deciding whether reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These should also be considered serious. Examples of such events are invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospitalisation.

#### **8.1.6. Solicited adverse events**

##### **8.1.6.1. Solicited local (injection-site) adverse events**

The following local (injection-site) AEs listed in Table 11 will be solicited:

**Table 11 Solicited local adverse events**

<b>Pain at injection site</b>
<b>Redness at injection site</b>
<b>Swelling at injection site</b>

If the subjects observe any large injection site reaction, they should contact the study personnel and to determine if a visit to the investigator's office for evaluation is necessary.

A large injection site reaction is:

- a swelling that measures more than 100 mm across where the vaccine was given, or
- a noticeable irregular/uneven swelling where the vaccine was given, or
- a noticeable increase in size of the arm that interferes with or prevents everyday activities (e.g., writing, use of computer, school attendance, sleeping, etc.).

In case of questions or uncertainties, the subject should contact the investigator by phone and the investigator will determine whether or not a visit should be arranged.

The investigator will record detailed information describing the AE on a specific large injection site reaction screen in the eCRF. An SAE report should also be completed if the large injection site reaction meets the definition of SAE.

##### **8.1.6.2. Solicited general adverse events**

The following general AEs listed in [Table 12](#) will be solicited:

**Table 12 Solicited general adverse events**

Fatigue
Fever*
Gastrointestinal symptoms†
Headache

\*Fever is defined as temperature  $\geq 37.5^{\circ}\text{C}$  for oral, axillary or tympanic route, or  $\geq 38.0^{\circ}\text{C}$  for rectal route

†Gastrointestinal symptoms include nausea, vomiting, diarrhoea and/or abdominal pain.

Note: Temperature will be recorded in the evening. Should additional temperature measurements be performed at other times of day, the highest temperature will be recorded in the eCRF.

### 8.1.7. Clinical laboratory parameters and other abnormal assessments qualifying as adverse events or serious adverse events

In absence of diagnosis, abnormal laboratory findings (e.g. clinical chemistry, haematology, urinalysis) or other abnormal assessments (e.g. medical imaging) that are judged by the investigator to be clinically significant will be recorded as AE or SAE if they meet the definition of an AE or SAE (refer to Sections 8.1.1 and 8.1.2). Clinically significant abnormal laboratory findings or other abnormal assessments that are present at baseline and significantly worsen following the start of the study will also be reported as AEs or SAEs. However, clinically significant abnormal laboratory findings or other abnormal assessments that are associated with the disease being studied, unless judged by the investigator as more severe than expected for the subject's condition, or that are present or detected at the start of the study and do not worsen, will not be reported as AEs or SAEs.

The investigator will exercise his or her medical and scientific judgement in deciding whether an abnormal laboratory finding or other abnormal assessment is clinically significant.

### 8.1.8. Adverse events of specific interest

AEs of specific interest for safety monitoring include the occurrence of

- NOCIs such as autoimmune disorders, asthma, type 1 diabetes and allergies. Refer to Section 8.1.8.1 for a non-exhaustive list of illnesses that can be recorded as NOCIs.
- GBS (to be reported as a SAE).
- Meningococcal disease (to be reported as an SAE).

See Section 8.2.3.5 for information on recording and reporting of these events.

#### 8.1.8.1. List of New Onset of Chronic Illnesses

Table 13 presents a non-exhaustive list of illnesses that can be recorded as NOCIs.

**Table 13 List of NOCIs**

Disease/Disorder	
Blood autoimmune disorders	Anaemia haemolytic autoimmune Antiphospholipid syndrome Cold type haemolytic anaemia Coombs positive haemolytic anaemia Idiopathic thrombocytopenic purpura Pernicious anaemia Warm type haemolytic anaemia Autoimmune thrombocytopenia Evan's syndrome Autoimmune neutropenia Thrombocytopenias
Endocrine autoimmune disorder	Basedow's disease Insulin autoimmune syndrome Polyglandular autoimmune syndrome type I Polyglandular autoimmune syndrome type II Autoimmune thyroiditis Diabetic mastopathy Lymphocytic hypophysitis Polyglandular autoimmune syndrome type III
Endocrine symptoms	Hyperthyroidism Hypothyroidism Goiter
Hepatic autoimmune disorder	Autoimmune hepatitis Biliary cirrhosis primary
Muscular autoimmune disorder	Myasthenia gravis Myasthenia gravis neonatal Polymyalgia Polypyalgia rheumatica Polymyositis Ocular myasthenia Myasthenia gravis crisis
Lupus erythematosus and associated conditions	Lupoid hepatic cirrhosis Lupus encephalitis Lupus nephritis SLE arthritis Systemic lupus erythematosus Systemic lupus erythematosus rash Lupus-like syndrome Cutaneous lupus erythematosus Lupus pneumonitis Neonatal lupus erythematosus Lupus vasculitis Pericarditis lupus Lupus endocarditis Peritonitis lupus Neuropsychiatric lupus

Disease/Disorder	
Autoimmune disorders NEC	Ankylosis spondylitis Cryoglobulinaemia Gastritis atrophic Goodpasture's syndrome Keratoconjunctivitis sicca Keratoderma blenorrhagica Mixed connective tissue disease Reiter's syndrome Sicca syndrome Sjogren's syndrome Sympathetic ophthalmia Leukoencephalomyelitis Toxic oil syndrome Cryofibrinogenaemia Encephalitis allergic Nephritis autoimmune Acute haemorrhagic leukoencephalitis Autoimmune disorder
Rheumatoid arthritis and associated conditions	Felty's syndrome Rheumatoid arthritis Rheumatoid lung Rheumatoid vasculitis Rheumatoid nodule Juvenile arthritis Laryngeal rheumatoid arthritis
Scleroderma and associated disorders	CREST syndrome Morphoea Scleroderma Systemic sclerosis Systemic sclerosis pulmonary Scleroderma renal crisis
Skin autoimmune disorders NEC	Benign familial pemphigus Dermatitis herpetiformis Dermatomyositis Eosinophilic fasciitis Herpes gestationis Linear IgA disease Pemphigoid Pemphigus Vitiligo
Acute and chronic thyroiditis	Thyroiditis Thyroiditis acute Thyroiditis chronic Thyroiditis subacute Autoimmune thyroiditis
Optic neuritis	Optic neuritis Optic neuritis retrobulbar Vision blurred Blindness Visual acuity reduced Visual evoked potential abnormality

Disease/Disorder	
Multiple sclerosis	Multiple sclerosis Demyelinating disorder Gait disturbances Muscle weakness Paraesthesias (Cognitive impairment) (Nuclear magnetic resonance imaging brain abnormal)
Transverse myelitis	Myelitis Transverse Muscle weakness Low back pain Paraesthesias and dysaesthesias Paralysis (Urinary retention) (Neurogenic bladder)
Guillain-Barre syndrome	Guillain-Barre syndrome Muscle weakness Paraesthesias and dysaesthesias
Diabetes mellitus insulin-dependent	Diabetes mellitus Diabetes mellitus (incl. subtypes) Glucose metabolism disorders (incl. diabetes mellitus)
Uveitis	Uveitis Eye pain Eye redness Photophobia
Glomerulonephritis	Lupus nephritis Proteinuria Haematuria Glomerular filtration rate decreased (Hypoproteinemia) (Oedema) Blood urea increased Blood creatinine increase
Inflammatory bowel disease	Inflammatory bowel disease
Crohn's disease	Crohn's disease
Ulcerative colitis	Ulcerative colitis Rectal bleeding
Coeliac disease	Coeliac disease
Sarcoidosis	Sarcoidosis Angiotensin converting enzyme increased
Asthma	Asthma
Allergies	Immune system disorders Allergic conditions
Auto immunity analyses	
Asthmatic crisis	Asthmatic crisis

### 8.1.9. Pregnancy

Female subjects who become pregnant after the vaccination may continue the study at the discretion of the investigator.

While pregnancy itself is not considered an AE or SAE, any adverse pregnancy outcome or complication or elective termination of a pregnancy for medical reasons will be recorded and reported as an AE or a SAE.

Note: The pregnancy itself should always be recorded on an Exposure During Pregnancy (EDP) form.

The following should always be considered as SAE and will be reported as described in Sections 8.3.1 and 8.3.2:

- Spontaneous pregnancy loss, including:
  - spontaneous abortion, (spontaneous pregnancy loss before/at 22 weeks of gestation)
  - ectopic and molar pregnancy
  - stillbirth (intrauterine death of foetus after 22 weeks of gestation).

Note: the 22 weeks cut-off in gestational age is based on WHO-ICD 10 noted in the EMA Guideline on pregnancy exposure [EMA 2006]. It is recognized that national regulations might be different.

- Any early neonatal death (i.e. death of a live born infant occurring within the first 7 days of life).
- Any congenital anomaly or birth defect (as per [CDC MACDP] guidelines) identified in the offspring of a study subject (either during pregnancy, at birth or later) regardless of whether the foetus is delivered dead or alive. This includes anomalies identified by prenatal ultrasound, amniocentesis or examination of the products of conception after elective or spontaneous abortion.

Furthermore, any SAE occurring as a result of a post-study pregnancy AND considered by the investigator to be reasonably related to the investigational vaccine will be reported to Pfizer as described in Section 8.3.2. While the investigator is not obligated to actively seek this information from former study participants, he/she may learn of a pregnancy through spontaneous reporting.

## **8.2. Detecting and recording adverse events, serious adverse events and pregnancies**

### **8.2.1. Time period for detecting and recording adverse events, serious adverse events and pregnancies**

All AEs starting one month (i.e. 30 days) following administration of the dose of study vaccine must be recorded into the appropriate section of the eCRF, irrespective of intensity or whether or not they are considered vaccination-related.

The time period for collecting and recording SAEs will begin at the receipt of study vaccine and will end one month (i.e. study end) following administration of the dose of study vaccine for each subject. See Section 8.3 for instructions on reporting of SAEs.

SAEs that are related to the investigational vaccine and any event related to lack of vaccine efficacy will be collected and recorded from the subject's last visit in the

persistence study MENACWY-TT-043 EXT:036 Y2, 3, 4, 5 (112148) until the subject is discharged from the study.

In addition to the above-mentioned reporting requirements and in order to fulfil international reporting obligations, SAEs that are related to study participation (i.e. protocol-mandated procedures, invasive tests, a change from existing therapy) will be collected and recorded from the time the subject consents to participate in the study until she/he is discharged from the study.

All AEs/SAEs leading to withdrawal from the study will be collected and recorded from the time of the receipt of study vaccine.

The time period for collecting and recording pregnancies will begin from administration of the study vaccine and will end one month (i.e. study end) following administration of the study vaccine. See Section [8.3](#) for instructions on reporting of pregnancies.

Occurrences of NOCIs (e.g. auto-immune disorders, asthma, type 1 diabetes, allergies) will be recorded from administration of the study vaccine dose until one month (i.e. study end) post administration of the study vaccine, whether or not they are considered to be possibly related to vaccine administration. Medical documentation of the events will be reported either as an unsolicited AE or as an SAE as appropriate in the eCRF.

Occurrences of GBS will be recorded from administration of the study vaccine dose until one month (i.e. study end) post administration of the study vaccine. Clinical details should be obtained as outlined in the 'Potential immune mediated disorders: standard questionnaires and list of preferred terms'. All occurrences of GBS have to be reported as SAEs.

An overview of the protocol-required reporting periods for AEs, SAEs, and pregnancies is given in [Table 14](#).



**Table 14 Reporting periods for adverse events, serious adverse events and pregnancies**

Study activity	Last visit done in study MenACWY-TT-036 (109069) or in the study MENACWY-TT-043 EXT:036 Y2, 3, 4, 5 (112148)	Pre-vacc <sup>*,1</sup>	Booster Vacc. <sup>1</sup>	4 days (Days 0-3) Post-vacc. <sup>1</sup>	31 days (Days 0-30) Post-vacc. <sup>1</sup>
			Visit 1 Month 120	Month 120 + 3 days	Visit 2 Month 121
Reporting of solicited local and general Adverse Events (AEs)					
Reporting of unsolicited AEs					
Reporting of NOCI <sup>2</sup>					
Reporting of GBS <sup>3</sup>					
Reporting of all Serious Adverse Events (SAEs) <sup>4</sup>					
Reporting of pregnancies <sup>5</sup>					
Recording of SAEs related to study vaccination and any event related to lack of vaccine efficacy since the previous visit. <sup>4,6</sup>					
Recording of SAEs related to study participation					

\*i.e Consent obtained.

<sup>1</sup> Vacc.: vaccination; Pre-vacc.: pre-vaccination; Post-vacc.: post-vaccination.

<sup>2</sup> NOCI = New Onset Of Chronic Illness(es) (e.g. autoimmune disorders, asthma, type I diabetes and allergies [a non-exhaustive list of NOCIs is provided in Table 13]). These AEs are collected from the day of the booster vaccination (Day 0) until one month [30 days] post-booster vaccination.

<sup>3</sup> In the event of Guillain Barré Syndrome (GBS), subjects should be contacted to obtain clinical details as outlined in the 'Potential immune mediated disorders: standard questionnaires and list of preferred terms'. All occurrences of GBS have to be reported as SAEs.

<sup>4</sup> All SAEs are collected from the day of the booster vaccination (Day 0) until one month [30 days] post-booster vaccination. Occurrence of meningococcal diseases should be documented in the SAE report in the eCRF.

<sup>5</sup> Pregnancies occurring between the booster vaccination (Day 0) and one month after vaccination (Day 30) will be recorded. If, after having been vaccinated, a subject is found to have been pregnant at vaccination, the pregnancy will be recorded as an exclusion criterion.

<sup>6</sup> Subjects will be questioned at entry of study C0921005 (MENACWY-TT-101 EXT:036 Y10 ) whether any SAEs occurred since the subject's last visit in MenACWY-TT-036 (109069) study or in the MenACWY- TT-043 EXT:036 Y2, 3, 4, 5 (112148) persistence study.

## **8.2.2. Post-Study adverse events and serious adverse events**

A post-study AE/SAE is defined as any event that occurs outside of the AE/SAE reporting period defined in Table 14. Investigators are not obligated to actively seek AEs or SAEs in former study participants. However, if the investigator learns of any SAE at any time after a subject has been discharged from the study, and he/she considers the event reasonably related to the investigational vaccine/product, the investigator will promptly report the SAEs to Pfizer.

## **8.2.3. Evaluation of adverse events and serious adverse events**

### **8.2.3.1. Active questioning to detect adverse events and serious adverse events**

As a consistent method of collecting AEs, the subject should be asked a non-leading question such as:

*‘Have you felt different in any way since receiving the vaccine or since the previous visit?’*

When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital progress notes, laboratory and diagnostics reports) relative to the event. The investigator will then record all relevant information regarding an AE/SAE in the eCRF. The investigator is not allowed to send photocopies of the subject’s medical records to Pfizer instead of appropriately completing the SAE form and CRF. However, there may be instances when copies of medical records for certain cases are requested by Pfizer. In this instance, all subject identifiers will be blinded on the copies of the medical records prior to submission to Pfizer.

The investigator will attempt to establish a diagnosis pertaining to the event based on signs, symptoms, and/or other clinical information. In such cases, the diagnosis should be documented as the AE/SAE and not the individual signs/symptoms.

**8.2.3.2. Assessment of adverse events****8.2.3.2.1. Assessment of intensity**

The intensity of the following solicited AEs will be assessed as described:

**Table 15 Intensity scales for solicited symptoms**

Adverse Event	Intensity grade	Parameter
Pain at injection site	0	None
	1	Mild: Any pain neither interfering with nor preventing normal every day activities.
	2	Moderate: Painful when limb is moved and interferes with every day activities.
	3	Severe: Significant pain at rest. Prevents normal every day activities.
Redness at injection site		Record greatest surface diameter in mm
Swelling at injection site		Record greatest surface diameter in mm
Fever*		Record greatest temperature in °C
Headache	0	Normal
	1	Mild: Headache that is easily tolerated
	2	Moderate: Headache that interferes with normal activity
	3	Severe: Headache that prevents normal activity
Fatigue	0	Normal
	1	Mild: Fatigue that is easily tolerated
	2	Moderate: Fatigue that interferes with normal activity
	3	Severe: Fatigue that prevents normal activity
Gastrointestinal symptoms (nausea, vomiting, diarrhoea and/or abdominal pain)	0	Gastrointestinal symptoms normal
	1	Mild: Gastrointestinal symptoms that are easily tolerated
	2	Moderate: Gastrointestinal symptoms that interfere with normal activity
	3	Severe: Gastrointestinal symptoms that prevent normal activity

\* Fever is defined as temperature  $\geq 37.5^{\circ}\text{C}$  for oral, axillary or tympanic route, or  $\geq 38.0^{\circ}\text{C}$  for rectal route. The preferred route for recording temperature in this study will be oral.

The maximum intensity of local injection site redness/swelling will be scored as follows:

0	:	None
1	:	$> 0 - \leq 20 \text{ mm}$
2	:	$> 20 - \leq 50 \text{ mm}$
3	:	$> 50 \text{ mm}$

The maximum intensity of fever will be scored as follows for oral/axillary or tympanic route:

0	:	$< 37.5^{\circ}\text{C}$
1	:	$\geq 37.5^{\circ}\text{C} - \leq 38.5^{\circ}\text{C}$
2	:	$> 38.5^{\circ}\text{C} - \leq 39.5^{\circ}\text{C}$
3	:	$> 39.5^{\circ}\text{C}$

The investigator will assess the maximum intensity that occurred over the duration of the event for all unsolicited AEs (including SAEs) recorded during the study. The assessment will be based on the investigator's clinical judgement.

The intensity should be assigned to one of the following categories:

- 1 (mild) = An AE which is easily tolerated by the subject, causing minimal discomfort and not interfering with everyday activities.
- 2 (moderate) = An AE which is sufficiently discomforting to interfere with normal everyday activities.
- 3 (severe) = An AE which prevents normal, everyday activities  
Such an AE would, for example, prevent attendance at work/school and would necessitate the administration of corrective therapy.

An AE that is assessed as Grade 3 (severe) should not be confused with a SAE. Grade 3 is a category used for rating the intensity of an event; and both AEs and SAEs can be assessed as Grade 3. An event is defined as 'serious' when it meets one of the pre-defined outcomes as described in Section 8.1.2.

#### **8.2.3.2.2. Assessment of causality**

The definitions for 'NO' and 'YES' have been written in such a way that all events that have been attributed a 'NO' can be pooled with events which in the primary vaccination study were determined to be 'not related' or 'unlikely to be related' to vaccination. Those events that are attributed a 'YES' can be pooled with those events that in the past were determined to have a 'suspected' or 'probable' relationship to vaccination in the primary vaccination study.

The investigator is obligated to assess the relationship between investigational vaccine/product and the occurrence of each unsolicited AE (including SAEs) and for general solicited AEs. The investigator will use clinical judgement to determine the relationship. Alternative plausible causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the event to the investigational vaccine/product will be considered and investigated. The investigator will also consult the CDS to determine his/her assessment.

There may be situations when a SAE has occurred and the investigator has minimal information to include in the initial report to Pfizer. However, it is very important that the investigator always makes an assessment of causality for every event prior to submission of the SAE report to Pfizer. The investigator may change his/her opinion of causality in light of follow-up information and update the SAE information accordingly. The causality assessment is one of the criteria used when determining regulatory reporting requirements.

In case of concomitant administration of multiple vaccines, it may not be possible to determine the causal relationship of general AEs to the individual vaccines administered. The investigator should, therefore, assess whether the AE could be causally related to vaccination rather than to the individual vaccines.

All solicited local (injection site) reactions will be considered causally related to vaccination. Causality of all other AEs should be assessed by the investigator using the following question:

*Is there a reasonable possibility that the AE may have been caused by the investigational vaccine/product?*

- YES : There is a reasonable possibility that the vaccine(s) contributed to the AE.
- NO : There is no reasonable possibility that the AE is causally related to the administration of the study vaccine(s). There are other, more likely causes and administration of the study vaccine(s) is not suspected to have contributed to the AE.

If an event meets the criteria to be determined as ‘serious’ (see Section 8.1.2), additional examinations/tests will be performed by the investigator in order to determine ALL possible contributing factors for each SAE.

Possible contributing factors include:

- Medical history.
- Other medication.
- Protocol required procedure.
- Other procedure not required by the protocol.
- Lack of efficacy of the vaccine, if applicable.
- Erroneous administration.
- Other cause (specify).

#### **8.2.3.3. Assessment of outcomes**

The investigator will assess the outcome of all unsolicited AEs (including SAEs) recorded during the study as:

- Recovered/resolved.
- Recovering/resolving.
- Not recovered/not resolved.
- Recovered with sequelae/resolved with sequelae.
- Fatal (SAEs only).

#### **8.2.3.4. Medically attended visits**

For each solicited and unsolicited symptom the subject experiences, the subject will be asked if he/she received medical attention defined as hospitalisation, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. This information will be recorded in the eCRF.

#### **8.2.3.5. Adverse events of specific interest**

AEs of specific interest for safety monitoring include:

- NOCIs such as autoimmune diseases, asthma, type I diabetes and allergies. Refer to Section 8.1.8.1 for a non-exhaustive list of illnesses that can be recorded as NOCI.
- GBS.
- Meningococcal disease.

Occurrences of NOCIs will be reported up to one month after the vaccine dose regardless of seriousness and whether or not they are considered to be possibly related to the treatment administration. Medical documentation of the events will be reported either as an unsolicited AE or as an SAE as appropriate in the eCRF.

Occurrences of GBS will be reported up to one month after the vaccine dose. Clinical details should be obtained as outlined in the 'Potential immune mediated disorders: standard questionnaires and list of preferred terms'. All occurrences of GBS have to be reported as an SAE.

Occurrences of meningococcal disease will be reported during the entire course of the study up to the study end and have to be reported as an SAE.

### **8.3. Reporting of serious adverse events, pregnancies, and other events**

#### **8.3.1. Prompt reporting of serious adverse events, pregnancies, and other events**

SAEs, including those due to GBS and invasive meningococcal disease, that occur in the time period defined in Section 8.2 will be reported promptly within the timeframes described in Table 16, once the investigator determines that the event meets the protocol definition of a SAE.

Pregnancies that occur in the time period defined in Section 8.2 will be reported promptly within the timeframes described in Table 16, once the investigator becomes aware of the pregnancy.

**Table 16 Timeframes for submitting serious adverse event, exposure during pregnancy and other events reports**

Type of Event	Initial Reports		Follow-up of Relevant Information on a Previous Report	
	Timeframe	Documents	Timeframe	Documents
All serious adverse events (SAEs)	24 hours*	paper SAE report	24 hours*	paper SAE report
Pregnancies	24 hours*	paper SAE and EDP reports	24 hours*	paper SAE and EDP reports
Guillain Barré Syndrome	24 hours*	paper SAE report	24 hours*	paper SAE report
Invasive Meningococcal disease	24 hours*	paper SAE report	24 hours*	paper SAE report

\* Timeframe allowed after receipt or awareness of the information.

### 8.3.2. Completion and transmission of SAE reports

Once an investigator becomes aware that a SAE has occurred in a study subject, the investigator (or designee) must complete the information in the paper SAE report WITHIN 24 HOURS. The SAE report will always be completed as thoroughly as possible with all available details of the event. Even if the investigator does not have all information regarding a SAE, the report should still be completed within 24 hours. Once additional relevant information is received, the report should be updated WITHIN 24 HOURS.

The investigator will always provide an assessment of causality at the time of the initial report.

### 8.3.3. Completion and transmission of pregnancy reports

Once the investigator becomes aware that a subject is pregnant, the investigator (or designee) must complete the required information onto the EDP report WITHIN 24 hours of awareness of the exposure.

Note: Conventionally, the Estimated Gestational Age (EGA) of a pregnancy is dated from the first day of the Last Menstrual Period (LMP) of the cycle in which a woman conceives. If the LMP is uncertain or unknown, dating of EGA and the estimated date of delivery should be estimated by ultrasound examination and recorded in the pregnancy report.

### 8.3.4. Updating of SAE and pregnancy information after *removal of write access to the subject's eCRF*

When additional SAE or pregnancy information is received after removal of the write access to the subject's eCRF, new or updated information should be recorded on a paper report, with all changes signed and dated by the investigator. The updated report should be faxed to Pfizer within the designated reporting time frames specified in Table 16.

### **8.3.5. Regulatory reporting requirements for serious adverse events**

The investigator will promptly report all SAEs to Pfizer in accordance with the procedures detailed in Section 8.3.1. Pfizer has a legal responsibility to promptly notify, as appropriate, both the local regulatory authority and other regulatory agencies about the safety of a product under clinical investigation. Prompt notification of SAEs by the investigator to Pfizer is essential so that legal obligations and ethical responsibilities towards the safety of other subjects are met.

Investigator safety reports are prepared according to the current Pfizer policy and are forwarded to investigators as necessary. An investigator safety report is prepared for a SAE(s) that is both attributable to the investigational vaccine/product and unexpected. The purpose of the report is to fulfil specific regulatory and GCP requirements, regarding the product under investigation.

### **8.4. Follow-up of adverse events, serious adverse events, and pregnancies**

#### **8.4.1. Follow-up of adverse events and serious adverse events**

##### **8.4.1.1. Follow-up during the study**

After the initial AE/SAE report, the investigator is required to proactively follow each subject and provide additional relevant information on the subject's condition to Pfizer (within 24 hours for SAEs; refer to [Table 16](#)).

All SAEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts until the end of the study.

All AEs documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts until study end.

NOCIs and GBS documented at a previous visit/contact and designated as not recovered/not resolved or recovering/resolving will be reviewed at subsequent visits/contacts until study end.

##### **8.4.1.2. Follow-up after the subject is discharged from the study**

The investigator will follow subjects:

- with SAEs, or subjects withdrawn from the study as a result of an AE, until the event has resolved, subsided, stabilised, disappeared, or until the event is otherwise explained, or the subject is lost to follow-up.
- with other AEs of specific interest (i.e. NOCIs, GBS, meningococcal disease) until one month after the vaccine dose or until the subject is lost to follow-up.



If the investigator receives additional relevant information on a previously reported SAE, he/she will provide this information to Pfizer using a paper SAE and/or EDP report as applicable.

Pfizer may request that the investigator performs or arranges the conduct of additional clinical examinations/tests and/or evaluations to elucidate as fully as possible the nature and/or causality of the AE or SAE. The investigator is obliged to assist. If a subject dies during participation in the study or during a recognised follow-up period, Pfizer will be provided with any available post-mortem findings, including histopathology.

#### **8.4.2. Follow-up of pregnancies**

Pregnant subjects will be followed to determine the outcome of the pregnancy. At the end of the pregnancy, whether full-term or premature, information on the status of the mother and child will be forwarded to Pfizer using the EDP report and the SAE report if applicable. Generally, the follow-up period doesn't need to be longer than six to eight weeks after the estimated date of delivery.

Regardless of the reporting period for SAEs for this study, if the pregnancy outcome is a SAE, it should always be reported as SAE.

#### **8.5. Treatment of adverse events**

Treatment of any AE is at the sole discretion of the investigator and according to current good medical practice. Any medication administered for the treatment of an AE should be recorded in the subject's eCRF (refer to Section 6.5).

#### **8.6. Subject card**

To facilitate access to appropriately qualified medical personnel on study-related medical questions or problems, subjects are provided with a contact card. The contact card contains, at a minimum, protocol and investigational compound identifiers, subject study numbers, contact information for the investigational site, and contact details for a contact center in the event that the investigational site staff cannot be reached to provide advice on a medical question or problem originating from another healthcare professional not involved in the subject's participation in the study. The contact number can also be used by investigational staff if they are seeking advice on medical questions or problems; however, it should be used only in the event that the established communication pathways between the investigational site and the study team are not available. It is therefore intended to augment, but not replace, the established communication pathways between the investigational site and the study team for advice on medical questions or problems that may arise during the study. The contact number is not intended for use by the subject directly, and if a subject calls that number, he or she will be directed back to the investigational site.

Subjects must be instructed to keep subject cards in their possession at all times.

## **9. SUBJECT COMPLETION AND WITHDRAWAL**

### **9.1. Subject completion**

A subject who returns for the concluding visit foreseen in the protocol is considered to have completed the study.

### **9.2. Subject withdrawal**

Subjects who are withdrawn because of SAEs/AEs must be clearly distinguished from subjects who are withdrawn for other reasons. Investigators will follow subjects who are withdrawn as result of an SAE/AE until resolution of the event (see Section [8.4.1.2](#)).

Withdrawals will not be replaced.

#### **9.2.1. Subject withdrawal from the study**

From an analysis perspective, a 'withdrawal' from the study refers to any subject who did not come back for the concluding visit foreseen in the protocol.

All data collected until the date of withdrawal/last contact of the subject will be used for the analysis.

A subject is considered a 'withdrawal' from the study when no study procedure has occurred, no follow-up has been performed and no further information has been collected for this subject from the date of withdrawal/last contact.

Investigators will make an attempt to contact those subjects who do not return for scheduled visits or follow-up. Lost to follow-up is defined by the inability to reach the subject after a minimum of 2 documented phone calls, faxes, or e-mails as well as lack of response by the subject to 1 registered mail letter. All attempts should be documented in the subject's medical records.

Information relative to the withdrawal will be documented in the eCRF. The investigator will document whether the decision to withdraw a subject from the study was made by the subject himself/herself or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event.
- Non-serious adverse event.
- Protocol violation (specify).
- Consent withdrawal, not due to an adverse event\*.
- Moved from the study area.
- Lost to follow-up.
- Other (specify).

\*In case a subject is withdrawn from the study because he/she has withdrawn consent, the investigator will document the reason for withdrawal of consent, if specified by the subject, in the CRF.

Subjects who are withdrawn from the study because of SAEs/AEs must be clearly distinguished from subjects who are withdrawn for other reasons. Investigators will follow subjects who are withdrawn from the study as result of a SAE/AE until resolution of the event (see Section 8.4.1.2).

### 9.2.2. Subject withdrawal from study vaccine

A 'withdrawal' from the study vaccine refers to any subject who does not receive the complete treatment, i.e., when no further planned dose is administered from the date of withdrawal. A subject withdrawn from the study vaccine may not necessarily be withdrawn from the study as further study procedures or follow-up may be performed (safety or immunogenicity) if planned in the study protocol.

Information relative to premature discontinuation of the study vaccine will be documented on the Vaccine Administration page/screen of the eCRF. The investigator will document whether the decision to discontinue further vaccination/treatment was made by the subject himself/herself, by the subject's parent(s) or LAR(s), or by the investigator, as well as which of the following possible reasons was responsible for withdrawal:

- Serious adverse event.
- Non-serious adverse event.
- Other (specify).

## 10. STATISTICAL METHODS

### 10.1. Primary endpoint

Immunogenicity with respect to the components of the investigational vaccine one month after booster vaccination with MenACWY-TT vaccine (primary readouts):

- rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA MenY booster response\*.

\*Booster response to meningococcal antigens (A, C, W-135 and Y) is defined as:

- For initially seronegative subjects (pre-vaccination rSBA titer below 1:8): rSBA antibody titer  $\geq$  1:32 one month after vaccination, and
- For initially seropositive subjects (pre-vaccination rSBA titer  $\geq$  1:8): at least four-fold increase in rSBA titers from pre-vaccination to one month after vaccination.

## 10.2. Secondary endpoints

Immunogenicity with respect to the components of the investigational vaccine prior to and one month after booster vaccination with MenACWY-TT vaccine (secondary readouts):

- rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY titres  $\geq 1:8$ ,  $\geq 1:128$  and GMTs.
- Anti-TT concentrations  $\geq 0.1$  IU/mL,  $\geq 1.0$  IU/mL and GMCs.

### Safety and reactogenicity

- Occurrence of solicited local and general symptoms within 4 days (Day 0 to Day 3) after MenACWY-TT booster vaccination.
- Occurrence of unsolicited AEs, within 31 days (Day 0 to Day 30) after MenACWY-TT booster vaccination.
- Occurrence of all SAEs, GBS and NOCIs [e.g. asthma, autoimmune disorders, type I diabetes, allergies] within 31 days (Day 0 to Day 30) after MenACWY-TT booster vaccination.
- Occurrence of SAEs related to primary vaccination and any event related to lack of vaccine efficacy (i.e. meningococcal disease) from the subject's last visit in the primary study MenACWY-TT-036 (109069) or in the persistence study MenACWY-TT-043EXT:036 Y2, 3, 4, 5 (112148) until entry in study C0921005 (MenACWY-TT-101EXT:036 Y10) (116724).

## 10.3. Determination of sample size

The sample size of this study with respect to the analysis of safety and immunogenicity post-booster is driven by the sample size of the primary vaccination study MenACWY-TT-036 (109069), the enrolment rate in the persistence extension study of MenACWY-TT-036 [MenACWY-TT-043EXT036 Y2, 3, 4 and 5 (112148)] and the estimated number of potential participating subjects based on the feedback from the site participating in this extension study. Subjects from the Philippines who received either MenACWY-TT or *Mencevax ACWY* vaccine will be eligible for this study if they meet the inclusion/exclusion criteria.

Subjects from the Philippines that were vaccinated in the MenACWY-TT-036 at the participating site will be invited to participate to this study with approximately 200 subjects expected to participate.

For the analysis at Month 121, one month after the booster vaccination, it is estimated that approximately 10% of the subjects will not be evaluable. Around 180 subjects will be included in the Booster ATP cohort of immunogenicity (135 in the ACWY-TT group and 45 in the MenPS group).

The primary objective of this study is to evaluate the immunogenicity of the booster dose in terms of the percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135

and rSBA-MenY booster response.

Table 17 illustrates the precision one can expect for percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY booster response from a group of 180 subjects.

**Table 17 Exact 95% confidence intervals of the percentage of subjects with rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY booster response**

Approx. %	ACWY-TT group Exact 2-sided 95% CI (N =135)		MenPS group Exact 2-sided 95% CI (N =45)	
	Lower Limit (LL)	Upper Limit (LL)	Lower Limit (UL)	Upper Limit (UL)
20	13.6	27.7	9.6	34.6
30	22.8	38.9	18.2	46.6
40	31.7	48.8	25.7	55.7
50	41.6	59.1	35.8	66.3
60	51.2	68.3	44.3	74.3
70	61.9	77.9	55.7	83.6
80	72.3	86.4	65.4	90.4
90	84.1	94.8	78.8	97.5
100	97.3	100.0	92.1	100.0

#### 10.4. Study cohorts/ data sets to be analysed

A total of 5 cohorts are defined for the purpose of analysis.

##### 10.4.1. Booster Total Vaccinated cohort

The Booster Total Vaccinated cohort for safety will include all vaccinated subjects in the study MenACWY-TT-036 (109069) with a MenACWY-TT booster vaccine administration documented.

For the analysis of immunogenicity post-booster vaccination the Booster Total Vaccinated cohort will include all subjects for whom data concerning post-booster immunogenicity endpoint measures are available.

##### 10.4.2. Booster According-to-protocol cohort for safety

The Booster ATP cohort for safety will include all subjects:

- who met all inclusion criteria and no exclusion criteria for the study
- who have received a dose of study vaccine MenACWY-TT or *Mencevax ACWY* in the primary study MenACWY-TT-036 (109069).
- who have received a MenACWY-TT booster dose.
- for whom the administration site of the booster vaccine is known.
- who have not received a vaccine not specified or forbidden in the protocol (subjects who received a vaccine not foreseen by the study protocol 30 days after the study vaccine dose will be eliminated from the Booster ATP cohort for safety if the

vaccine not foreseen by the protocol was administered before the post-vaccination blood sample).

- who were not excluded from the ATP cohort for persistence at Month 120, unless the reason for exclusion was either non-compliance with the protocol-defined serum sampling windows or a lack of availability of immunogenicity results at Month 120 (pre-booster vaccination).

#### **10.4.3. Booster According-to-protocol cohort for immunogenicity**

The Booster ATP cohort for immunogenicity will include all evaluable subjects (i.e. those meeting all eligibility criteria, complying with the procedures defined in the protocol and with no elimination criteria during the study) from the Booster ATP cohort for safety for whom assay results are available for antibodies against at least one study vaccine antigen component for the blood sample taken one month post-vaccination, and who were not administered a vaccine not foreseen by the study protocol before the post-vaccination blood sample.

The interval between Visit 1 and Visit 2 for inclusion in the Booster ATP cohort for immunogenicity will be defined as 21 to 48 days.

#### **10.4.4. Total cohort at Month 120**

The Total cohort at Month 120 will include all vaccinated subjects in the vaccination stage of study MenACWY-TT-036 (109069) who return for the Month 120 follow-up.

For the analysis of persistence, this will include all vaccinated subjects for whom data concerning persistence endpoint measures are available.

#### **10.4.5. According-to-protocol cohort for persistence at Month 120**

The ATP cohort for antibody persistence at Month 120 will include all evaluable subjects:

- who were eligible in study MenACWY-TT-036 (109069).
- who have received the primary vaccination with MenACWY-TT or *Mencevax ACWY* during study MenACWY-TT-036 (109069).
- who have available assay results for at least one tested antigen at Month 120.
- who have not received a meningococcal vaccine not planned in protocol MenACWY-TT-036 (109069) before Month 120.
- who do not have a history of meningococcal serogroup A, C, W-135, or Y disease prior to Month 120.
- who comply with the blood sampling intervals defined in Section 5.5 of the protocol.
- who do not have an immunocompromising medical condition.
- who have not received any immunosuppressant(s) or other immune-modifying drug(s), immunoglobulins, any blood products, investigational drugs, and/or investigational vaccines during the timeframe specified in the protocol.

- who were not excluded from the ATP cohort for immunogenicity in the primary study MenACWY-TT-036 (109069), and from the previous ATP persistence cohorts, unless the reason for exclusion was either non-compliance with the protocol-defined serum sampling windows or a lack of availability of immunogenicity results at a previous time point.

## 10.5. Derived and transformed data

### 10.5.1. Immunogenicity

- For a given subject and a given immunogenicity measurement, missing or non-evaluable measurements will not be replaced. Therefore, an analysis will exclude subjects with missing or non-evaluable measurements.
- The cut-off value is defined by the laboratory before the analysis and is described in [Section 5.7.3](#).
- A seronegative subject is a subject whose titre is below the cut-off value.
- A seropositive subject is a subject whose titre is greater than or equal to the cut-off value.
- The GMTs/GMCs calculations are performed by taking the anti-log of the mean of the log titre/concentration transformations. Antibody titres/concentrations below the cut-off value of the assay will be given an arbitrary value of half the cut-off value for the purpose of GMT/GMC calculation.
- rSBA booster response for serogroups A, C, W-135 and Y after the vaccine dose is defined as:
  - For initially seronegative subjects (pre-vaccination titer below the cut-off of 1:8): rSBA antibody titers post-vaccination titer  $\geq$  1:32 one month after vaccination, and
  - For initially seropositive subjects (pre-vaccination titer  $\geq$  1:8): rSBA antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination.
- Handling of missing data: for a given subject and a given immunogenicity measurement, missing or non-evaluable measurements will not be replaced.

## 10.6. Statistical analyses

### 10.6.1. Analysis of demographics/baseline characteristics

Demographic characteristics of each study cohort will be tabulated: age at booster vaccination (in years), gender and geographic ancestry.

The reason for not attending the post-booster visit among all subjects who received the booster vaccination will be summarized.

### 10.6.2. Analysis of post-booster immunogenicity

The analysis of post-booster immunogenicity will be based on the Booster ATP cohort for immunogenicity. If, for any group, the percentage of subjects who come back with serological results excluded from the Booster ATP cohort is higher than 5%, a second analysis based on the Booster Total Vaccinated cohort will be performed to complement the ATP analysis.

#### 10.6.2.1. Within group analysis

For each group, at each blood sampling time point (Month 120 and Month 121), for each antigen assessed:

- Percentage of subjects with rSBA booster response with 95% Confidence Intervals (CIs) will be calculated.
- GMTs/GMCs with 95% CIs will be tabulated.
- Percentages of subjects with titres/concentrations above proposed cut-offs and with 95% CIs will be calculated.
- The antibody titres/concentrations will be tabulated and also presented using reverse cumulative distribution curves.

CCI

CCI

#### 10.6.3. Analysis of antibody persistence

The analysis of antibody persistence will be based on the ATP cohort for persistence at Month 120. If, for any group, the percentage of subjects who come back with serological results excluded from the ATP cohort for persistence at Month 120 is higher than 5%, a second analysis based on the Total cohort at Month 120 will be performed to complement the ATP analysis.



#### 10.6.3.1. Within group analysis

For each group, at the Month 120 blood sampling time point, for each antigen assessed:

- GMTs with 95% CIs will be tabulated.
- Percentages of subjects with titres above proposed cut-offs and with 95% CIs will be calculated.
- The antibody titres will be tabulated and also presented using reverse cumulative distribution curves.

CCI

[REDACTED]

CCI

[REDACTED]

#### 10.6.4. Analysis of reactogenicity and safety

The analysis of safety will be done after administration of the booster dose only.

The primary analysis will be performed on the Booster Total Vaccinated cohort and, if more than 5% of the enrolled subjects are eliminated from the Booster ATP cohort for safety a second analysis will be performed on the Booster ATP cohort for safety to support the analyses of the Booster Total Vaccinated cohort.

For each group, after the MenACWY-TT booster vaccination:

The percentage of subjects with at least one local AE (solicited and unsolicited), with at least one general AE (solicited and unsolicited) and with any AE during the 4-day (Days 0-3) solicited follow-up period will be tabulated with exact 95% CI. The same calculations will be performed for symptoms rated as grade 3 and for symptoms related to vaccination.

The percentage of subjects reporting each individual solicited local (any grade, grade 3, medical advice) and general (any grade, grade 3, related, grade 3 and related, medical advice) AE during the 4-day follow-up period (Days 0-3) after vaccination and its exact 95% CI will be tabulated. Occurrence of fever will also be reported per 0.5°C cumulative increment as well as the percentage of subjects with oral temperature >39.5°C. Additionally, large injection site reactions will be described in detail.

The verbatim reports of unsolicited symptoms will be reviewed and the signs and symptoms will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) for Adverse Reaction Terminology. The percentage of subjects with unsolicited symptoms within 31 days post-booster vaccination (Days 0-30) and its exact 95% CI will be tabulated by group and by MedDRA preferred term. Similar tabulation will be done for grade 3 unsolicited symptoms, for unsolicited symptoms possibly related to vaccination and for grade 3 unsolicited symptoms possibly related to vaccination. The number and percentage of subjects who experienced SAE and new onset of chronic illness within 31 days following booster vaccination will be tabulated with exact 95% CI.

The percentage of subjects using concomitant medication (any medication, any antipyretic/analgesic, any antipyretic/analgesic taken prophylactically, respectively) during the 4-day and 31-day follow-up periods (Days 0-3 and Days 0-30, respectively) after vaccination will be summarized.

All reported SAEs related to primary vaccination and any event related to lack of vaccine efficacy from the subject's last visit in the primary study MenACWY-TT-036 (109069) or in the persistence study MENACWY-TT-043 EXT036 Y2, 3, 4, 5 (112148) to study entry in study C0921005 (MENACWY-TT-101 EXT:036 Y10 ) will be described in detail in a retrospective manner.

## **10.7. Interpretation of analyses**

All the analyses will be descriptive with the aim to characterise the immunogenicity within CCI study groups. CCI

## **10.8. Conduct of analyses**

Any deviations or changes from the original statistical plan outlined in this protocol will be described and justified in the final study report.

### **10.8.1. Sequence of analyses**

The analysis of immunogenicity, safety and reactogenicity reported during the entire study period up to one month after the booster vaccination (Month 121) will be performed as soon as the data has been cleaned. The results will be presented in a Clinical Study Report.

Statistical considerations for interim analyses

No statistical adjustment for interim analyses is required.

## **11. ADMINISTRATIVE MATTERS**

To comply with ICH GCP administrative obligations relating to data collection, monitoring, archiving data, audits, confidentiality and publications must be fulfilled.

### **11.1. electronic Case Report Form instructions**

A validated Pfizer defined electronic data collection tool will be used as the method for data collection.

In all cases, subject initials will not be collected nor transmitted to Pfizer. Subject data necessary for analysis and reporting will be entered/transmitted into a validated database or data system. Clinical data management will be performed in accordance with applicable Pfizer standards and data cleaning procedures.

While completed eCRFs are reviewed by a Pfizer or designee Site Monitor at the study site, omissions or inconsistencies detected by subsequent eCRF review may necessitate clarification or correction of omissions or inconsistencies with documentation and approval by the investigator or appropriately qualified designee. In all cases, the investigator remains accountable for the study data.

The investigator will be provided with the final version of the data generated at the investigational site once the database is archived and the study report is complete and approved by all parties.

### **11.2. Study Monitoring**

Pfizer or designee will monitor the study to verify that, amongst others, the:

- Data are authentic, accurate, and complete.
- Safety and rights of subjects are being protected.
- Study is conducted in accordance with the currently approved protocol, any other study agreements, GCP and all applicable regulatory requirements.

The investigator and the head of the medical institution (where applicable) agrees to allow the monitor direct access to all relevant documents.

The investigator must ensure provision of reasonable time, space and qualified personnel for monitoring visits.

Direct access to all study-site related and source data is mandatory for the purpose of monitoring review. The monitor will perform a eCRF review and a Source Data Verification (SDV). By SDV we understand verifying eCRF entries by comparing them with the source data that will be made available by the investigator for this purpose.

The Source Documentation Agreement Form describes the source data for the different data in the eCRF. This document should be completed and signed by the site monitor and investigator and should be filed in the monitor's and investigator's study file. Any data item for which the eCRF will serve as the source must be identified, agreed and documented in the source documentation agreement form.

For eCRF, the monitor will mark completed and approved screens at each visit.

Upon completion or premature discontinuation of the study, the monitor will conduct site closure activities with the investigator or site staff, as appropriate, in accordance with applicable regulations, GCP, and Pfizer procedures.

### **11.3. Record retention**

Following closure of the study, the investigator must maintain all site study records (except for those required by local regulations to be maintained elsewhere) in a safe and secure location. The records must be easily accessible, when needed (e.g. audit or inspection), and must be available for review in conjunction with assessment of the facility, supporting systems, and staff. Where permitted by applicable laws/regulations or institutional policy, some or all of these records can be maintained in a validated format other than hard copy (e.g. microfiche, scanned, electronic); however, caution needs to be exercised before such action is taken. The investigator must ensure that all reproductions are legible and are a true and accurate copy of the original and meet accessibility and retrieval standards, including re-generating a hard copy, if required. Furthermore, the investigator must ensure that an acceptable back-up of the reproductions exists and that there is an acceptable quality control procedure in place for making these reproductions.

Pfizer will inform the investigator/institution of the time period for retaining these records to comply with all applicable regulatory requirements. However, the investigator/institution should seek the written approval of the sponsor before proceeding with the disposal of these records. The minimum retention time will meet the strictest standard applicable to a particular site, as dictated by ICH GCP, any institutional requirements, applicable laws or regulations, or Pfizer standards/procedures; otherwise, the minimum retention period will default to 15 years.

The investigator/institution must notify Pfizer of any changes in the archival arrangements, including, but not limited to archival at an off-site facility, transfer of ownership of the records in the event the investigator leaves the site.

### **11.4. Quality assurance**

To ensure compliance with GCP and all applicable regulatory requirements, Pfizer may conduct a quality assurance audit. Regulatory agencies may also conduct a regulatory inspection of this study. Such audits/inspections can occur at any time during or after completion of the study. If an audit or inspection occurs, the investigator and institution agree to allow the auditor/inspector direct access to all relevant documents and to allocate his/her time and the time of his/her staff to the auditor/inspector to discuss findings and any relevant issues.

## **11.5. Posting of information on publicly available clinical trial registers and publication policy**

Pfizer fulfills its commitment to publicly disclose clinical trial results through posting the results of studies on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (ClinicalTrials.gov), the European Clinical Trials Database (EudraCT), and/or [www.Pfizer.com](http://www.Pfizer.com), and other public registries in accordance with applicable local laws/regulations.

In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and complete manner and are reported regardless of the outcome of the study or the country in which the study was conducted.

[www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Pfizer posts clinical trial US Basic Results on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) for Pfizer-sponsored interventional studies conducted in patients that evaluate the safety and/or efficacy of a Pfizer product, regardless of the geographical location in which the study is conducted. US Basic Results are submitted for posting within 1 year of the primary completion date for studies in adult populations or within 6 months of the primary completion date for studies in pediatric populations.

Primary completion date is defined as the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical study concluded according to the prespecified protocol or was terminated.

EudraCT

Pfizer posts EU Basic Results on EudraCT for all Pfizer-sponsored interventional studies that are in scope of EU requirements. EU Basic Results are submitted for posting within 1 year of the primary completion date for studies in adult populations or within 6 months of the primary completion date for studies in pediatric populations.

[www.Pfizer.com](http://www.Pfizer.com)

Pfizer posts Public Disclosure Synopses (clinical study report synopses in which any data that could be used to identify individual patients has been removed) on [www.Pfizer.com](http://www.Pfizer.com) for Pfizer-sponsored interventional studies at the same time the US Basic Results document is posted to [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

## **11.6. Provision of study results to investigators**

Where required by applicable regulatory requirements, an investigator signatory will be identified for the approval of the study report. The investigator will be provided reasonable access to statistical tables, figures, and relevant reports and will have the opportunity to review the complete study results at a Pfizer site or other mutually-agreeable location.

Pfizer will also provide the investigator with the full summary of the study results. The investigator is encouraged to share the summary results with the study subjects, as appropriate.

Pfizer supports the exercise of academic freedom and has no objection to publication by principal investigator of the results of the study based on information collected or generated by principal investigator, whether or not the results are favorable to the Pfizer product. However, to ensure against inadvertent disclosure of confidential information or unprotected inventions, the investigator will provide Pfizer an opportunity to review any proposed publication or other type of disclosure of the results of the study (collectively, "Publication") before it is submitted or otherwise disclosed.

The investigator will provide any publication to Pfizer at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, the investigator agrees to delay the disclosure for a period not to exceed an additional 60 days.

The investigator will, on request, remove any previously undisclosed confidential information before disclosure, except for any study- or Pfizer product-related information necessary to the appropriate scientific presentation or understanding of the study results.

If the study is part of a multicenter study, the investigator agrees that the first publication is to be a joint publication covering all study sites, and that any subsequent publications by the principal investigator will reference that primary publication. However, if a joint manuscript has not been submitted for publication within 12 months of completion or termination of the study at all participating sites, the investigator is free to publish separately, subject to the other requirements of this section.

For all publications relating to the study, the institution will comply with recognized ethical standards concerning publications and authorship, including Section II - "Ethical Considerations in the Conduct and Reporting of Research" of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, <http://www.icmje.org/index.html#authorship>, established by the International Committee of Medical Journal Editors.

Publication of study results is also provided for in the clinical study agreement (CSA) between Pfizer and the institution. In this section on publications by investigators, the defined terms shall have the meanings given to them in the CSA.

If there is any conflict between the CSA and any Attachments to it, the terms of the CSA control. If there is any conflict between this protocol and the CSA, this protocol will control as to any issue regarding treatment of study subjects, and the CSA will control as to all other issues.

## 11.7. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP

In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable competent authority in any area of the world, or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study vaccine, Pfizer should be informed immediately.

In addition, the investigator will inform Pfizer immediately of any urgent safety measures taken by the investigator to protect the study subjects against any immediate hazard, and of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.

## 12. COUNTRY SPECIFIC REQUIREMENTS

Not applicable.

## 13. REFERENCES

Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. *Clin Diagn Lab Immunol*. 2003;10(5):780-786.

Anonymous. Meningococcal Disease - New England, 1993-1998. *MMWR*. 1999;48(29):629-633.

Aplasca-De Los Reyes MR, Dimaano E, Macalalad N, et al. The investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults. *Hum Vaccin Immunother*. 2012;8(7):881-7.

Baxter R, Baine Y, Ensor K, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10-25 years of age. *Pediatr Infect Dis J*. 2011;30(3):e41-8.

Bermal N, Huang L, Dubey A, et al. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults. *Human Vaccines*. 2011;7(2):239-47.

Baxter R1, Reisinger K2, Block SL3, Izu A4, Odrlijin T4, Dull PM, Smolenov I, *J Pediatr*. 2014 Jun;164(6):1409-15.

Baxter R1, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M., *Pediatr Infect Dis J*. 2015 Aug 1.

Borrow R., Abad R., Trotter C. et al, Effectiveness of meningococcal serogroup C vaccine programmes. *Vaccine*. 2013;31:4477-4486.

Centers for Disease Control and Prevention Metropolitan Atlanta Congenital Defects Program (CDC MACDP) guidelines. Birth defects and genetic diseases branch 6-digit code for reportable congenital anomalies;  
<http://www.cdc.gov/ncbddd/birthdefects/documents/MACDPcode0807.pdf>

Cohn AC, NacNeil JR, Harrison LH, Hatcher C, et al. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. *Clin Infect Dis*. 2010; 50(2):184-191.

Dbaibo G, Van der Wielen M, Reda M, Medlej F, et al. The tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine. *Int J Infect Dis*, 2012a; 16(8): e608-615.

Dbaibo G, Macalalad N, Aplasca-De Los Reyes MR, et al. The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared to a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study. *Hum Vaccin Immunother*. 2012b;8(7):873-80.

Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 years and older: Results of an open-label, randomized, controlled trial. *Drugs Aging*. 2013;30(5):309-19.

EMA. Guideline on the exposure to medicinal products during pregnancy: need for post-authorization data (Doc. Ref. EMEA/CHMP/313666/2005 ) ‘adopted at Community level in May 2006);  
[http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2009/11/WC500011303.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf)

European Commission. Commission implementing decision of 20.04.2012. granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for “Nimenrix – Meningococcal Group A, C, W-135 and Y conjugate vaccine” a medicinal product for human use. C(2012)2813  
[http://ec.europa.eu/health/documents/community-register/2012/20120420120470/dec\\_120470\\_en.pdf](http://ec.europa.eu/health/documents/community-register/2012/20120420120470/dec_120470_en.pdf) Accessed 0513 November 20152.

Harrison LH. Epidemiological profile of meningococcal disease in the United States. *Clin Infect Dis*. 2010;50 Suppl 2:S37-44

Healy CM, Butler KM, Smith EO et-al. Influence of serogroup on the presentation, course, and outcome of invasive meningococcal disease in children in the Republic of Ireland, 1995-2000. *Clin. Infect. Dis*. 2002;34 (10): 1323-30.



Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. *Arch Pediatr Adolesc Med.* 2005; 159(10):907-913.

Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. *Vaccine.* 2010;28(3):744-53.

Knuf M, Pantazi-Chatzikonstantinou A, Pfletschinger U, et al. An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children. *Vaccine.* 2011;29(25):4264-73.

McComb J. The prophylactic dose of homologous tetanus antitoxin. *N. Engl. J. Med.* 1964; 270:175-178.

Memish Z, Dbaiibo G, Montellano M, et al. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine administered to 2-10 year olds is non-inferior to a licensed ACWY polysaccharide vaccine with an acceptable safety profile. *Pediatr Infect Dis J.* 2011;30(4):e56-62.

Menactra Approval Letter. April 2011.

<http://www.fda.gov/BiologicsBloodVaccine/Vaccines/ApprovedProducts/ucm252511.htm>. Accessed 23 September 2011.

Menactra Product Information. US. May 2009.

Menactra Product Monograph,. Canada. June 2012.

Menveo Highlights on Prescribing Information, US. August, 2013.

<http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf> Accessed 14 October 2015

Menveo Product Monograph, Canada. November 2014.

Menveo Consumer Medicine Information, Australia. July, 2015.

<https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-CMI-02476-3> Accessed 14 October 2015.

Menveo Summary of Product Characteristics, EU. December, 2014.

[http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/001095/WC500090147.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001095/WC500090147.pdf) Accessed 14 October 2015.

Maslanka SE, Gheesling LL, Libutti DE et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. *Clin. Diagn. Lab. Immunol.* 1997;4(2):156-167.

Mimouni D, Gdalevich M, Mandel Y et al. Meningococcal polysaccharide vaccination of military recruits in Israel: Preliminary assessment of vaccine effect. *Scan J Infect Dis.* 1998;30:263-264.

Newell KW, Leblanc DR, Edsall G et al. The serological assessment of a tetanus toxoid field trial. *Bull World Health Organ.* 1971;45(6):773-85.

Østergaard L, Lebacqz E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. *Vaccine.* 2009; 27(1):161-8.

Østergaard L, Silfverdal SA, Berglund J, et al. A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix<sup>®</sup> in subjects aged 11-17 years: an open, randomised, controlled trial. *Vaccine.* 2012;30(4):774-83.

Pollard AJ. Protein-polysaccharide conjugate vaccine failure. 2010, in: 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 4–8, 2010, Nice, France.

Rosenstein NE, Perkins BA, Stephens DS et al. Meningococcal disease. *N. Engl. J. Med.* 2001;344 (18): 1378-88

Tawfiq-Al JA, Memish ZA, The Hajj: Updated health hazards and current recommendations for 2012. *Rapid Communication. Eurosurveillance.* 2012: 17(41).

WHO. Expert Committee on Biological Standardization, 31st Report. *WHO Technical Report Series.* 1981;658:174-183.

WHO position paper on Meningococcal vaccines. *Weekly epidemiological record* No. 47, 2011; 86:521-540.

Vesikari T, Karvonen A, Bianco V, et al. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial. *Vaccine.* 2011;29(25):4274-84.

## APPENDIX A      LABORATORY ASSAYS

The following tests will be performed using the aliquots of serum:

Functional anti-meningococcal serogroup bactericidal activity (ie, rSBA-MenA, rSBA-MenC, rSBA-MenW-135, rSBA-MenY) will be determined by a serum bactericidal assay using rabbit complement (rSBA) at Public Health England (PHE) according to the Centers for Disease Control and Prevention (CDC) protocol [[Maslanka, 1997](#)]. rSBA titres will be expressed as the reciprocal of the highest serum dilution resulting in at least 50% reduction of meningococcal colony-forming units.

- Specific antibody against tetanus toxoid will be measured by dLIA. The cut-off of the assay is 0.1 IU/mL [[McComb, 1964](#); [Newell, 1971](#)].

**APPENDIX B      CLINICAL LABORATORIES****Table 18      Outsourced laboratories**

<b>Laboratory</b>	<b>Address</b>
Public Health England (PHE)	Vaccine Evaluation Unit Public Health England North West Manchester Medical Microbiology Partnership 2nd Floor, Clinical Sciences Building II Manchester Royal Infirmary Oxford Road, Manchester England, M13 9WZ
Pharmaceutical Product Development (PPD), Inc. Bioanalytical Laboratories	Bioanalytical Laboratories 2244 Dabney Road Richmond, VA 23230 USA

## Document Approval Record

**Document Name:**

C0921005 MENACWY-TT-101 EXT 036 Y10 (116724) Protocol Amendment 3 Clean Copy, 12 July 2017

**Document Title:**

A phase IIIb, open study to evaluate the immunogenicity, reactogenicity and safety of a booster dose of MenACWY-TT vaccine administered 10 years after healthy subjects aged 11-17 years received either MenACWY-TT vaccine (Nimenrix®) or Mencevax ACWY®

**Signed By:****Date(GMT)****Signing Capacity**

PPD

18-Jul-2017 16:21:38

Final Approval

PPD

19-Jul-2017 14:41:36

Final Approval